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DEVELOPMENT OF C5AR-TARGETED NANOPARTICLES FOR
DELIVERY OF VACCINES
Shailendra Bharadwaj Tallapaka, Ph.D.
University of Nebraska Medical Center, 2017

Since the early attempts of Benjamin Jesty at inducing immunity against
smallpox and the pioneering work of Edward Jenner, vaccination has been, and
continues to remain, the principal method of protection from diseases. However, most
of the successful vaccines have been against pathogens that do not have major
mechanisms to evade the immune system. So far, many life-threatening diseases like
hepatitis C, HIV infection, malaria etc., have been resistant to existing vaccination
strategies. Thus, there is an urgent need to develop new vaccination strategies that
can generate long-lived protective immunity against such pathogens.
The purpose of this thesis is to investigate the effect of targeting PLGA
nanoparticles to antigen-presenting cells using a novel immunostimulatory peptide
EP67 as the targeting moiety on the immune responses generated against the
encapsulating model antigen. In this study, we have shown that surface modification
of PLGA nanoparticles with EP67 simultaneously targets and activates BMDCs, which
results in enhanced antigen presentation to T-cells. Furthermore, we demonstrated
that respiratory immunization with EP67 surface-modified OVA-encapsulated PLGA
nanoparticles (i) increased protection against respiratory infection with LM-OVA by
significantly reducing bacteria (ii) increased magnitudes of OVA-specific CD4+/CD8+
T-cells in lungs and spleen, (iii) increased proportions of short-lived effector cells
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(SLECs), double positive effector cells (DPECs), and memory precursor effector cells
(MPECs) in lungs, (iv) increased effector memory MPECs and central memory
MPECs without affecting SLECs in spleen, and (v) affected the cytokine secretion
profile of splenocytes responsive to MHC-II epitope of OVA. Overall, this work
demonstrates the proof-of-concept that surface modification of PLGA nanoparticles
with EP67 can increase the efficacy of immune responses generated against the
encapsulated antigen.
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CHAPTER 1

GENERAL INTRODUCTION
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1.1 Introduction

Vaccination is arguably the greatest achievement of medical science, in terms
of the effect it had on improving human life expectancy. So far, mass immunization
programs have led to the complete eradication of smallpox and reduced the number
of reported cases of many diseases, including diphtheria, polio, measles, mumps,
rubella, CRS, and Haemophilus influenza, by more than 99% [1, 2]. Apart from
reducing morbidity and suffering in humans, vaccination also has a significant impact
on the global economy. In 2009, the routine childhood immunization program in the
United States (which includes diphtheria and tetanus toxoids and acellular pertussis,
Haemophilus

influenzae

type

b

conjugate,

inactivated

poliovirus,

measles/mumps/rubella, hepatitis V, varicella, 7-valent pneumococcal conjugate,
hepatitis A and rotavirus vaccines) has been expected to have prevented ~42,000
early deaths, 20 million cases of disease, with savings of $13.5 billion in direct costs
and $68.8 billion in societal costs [3].
1.2 Conventional vaccines

Vaccination is majorly a prophylactic pharmacotherapy that is aimed at
generating long-lived immune responses that can protect against infection by the
corresponding microbe. Conventional vaccines utilize either a live-attenuated strain
of a pathogen with low virulence or a killed pathogen to generate strong immune
responses. Although both of these vaccines are effective at generating protective
responses, primarily due to their resemblance to natural infection, they have many
disadvantages like (i) risk of reversion to virulence, (ii) safety concerns when used in
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immunocompromised patients, (iii) adverse side-effects in patients, (iv) and also a
need for refrigeration to maintain efficacy, which is an issue in developing countries
that may not have required facilities [4-6].
1.3 Subunit vaccines

To overcome the disadvantages of conventional vaccines, recent studies have
focused on developing vaccines that contain only specific pathogenic components
(subunits) that are recognized by the immune system. As these subunit vaccines do
not contain any harmful microbial components they are much safer to use in humans.
Subunit vaccines contain either whole protein antigens, which are purified directly
from the pathogen or synthesized using recombinant DNA technology, or antigenic
peptides that are chemically synthesized. However, subunit vaccines have low
immunogenicity and are not capable of generating effective immune responses; this
requires the addition of components known as adjuvants that can stimulate the
immune system. Currently, there are not many adjuvants that are approved for
human use and those approved adjuvants have limited capacity to generate cellmediated immune responses. Therefore, there remains a great need for developing
novel adjuvants and delivery systems that can improve the efficacy of vaccines [710].
1.4 Vaccine-induced immunity

The goal of vaccination is to generate long-lived antigen-specific immunological
memory that can quickly respond to pathogenic invasion and protect against the
development of disease [11]. Immunological memory is a hallmark of the adaptive
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immune system which consists of two major components – humoral and cellular
immunity. The success of a vaccine depends on whether it can generate the type of
immune response required to protect against the corresponding pathogen. However,
the type of immune response generated by a vaccine depends on its contents. For
example, vaccines containing live-attenuated pathogens are very potent at
generating both humoral and cellular responses.

On the other hand, vaccines

containing killed inactivated pathogens or antigenic proteins are weakly immunogenic
and are unable to generate strong cellular responses[12]. Furthermore, chronic
infectious diseases such as AIDS, tuberculosis, and herpes have multiple immune
evasive strategies, and so development of vaccines against such diseases requires
a thorough understanding of the immunological correlates of protection and the
virulence strategies of the pathogen [13].

1.4.1 Humoral immune responses

Protection of the host from infection by humoral immune responses involves
the production of antibodies by activated B-cells, which destroy extracellular
pathogens and prevent the spread of intracellular pathogens. Activation of B-cells
requires the binding of cognate antigen to B-cell receptors and interaction with
antigen-specific CD4+ helper T-cells that recognize the peptide-MHC-II complexes
derived from the antigen internalized by the B-cell. Some B-cells become plasma
cells and the rest will migrate to the germinal center, where they undergo somatic
hypermutation and B-cells that produce antibodies with the highest avidity are
selected. Helper T-cells promote the survival of germinal center B-cells through
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CD40-CD40L interactions and release various cytokines like IL-4, IL-5, IFN-γ and
TGF-β which regulate the production of different antibody classes. B-cells that survive
in the germinal center either differentiate into plasma cells which produce large
amounts of an antibody or become memory B-cells which produce small amounts of
antibodies (if any) [14].

Antibodies contribute to resistance by either directly neutralizing the pathogen,
or by coating the surface of a pathogen, which increases its phagocytosis
(opsonization) and activates the proteins of complement system via the classical
pathway. Until the early 21st century, it was largely accepted that antibody-mediated
responses provide immunity to extracellular pathogens while the immunity to
intracellular pathogens rely on cell-mediated immune responses. However, persisting
antibody production after immunization is considered as a sign of successful
vaccination, due to the fact that antibody-mediated immunity induced by many viral
vaccines confers protection against infection. This is because most pathogens are
susceptible to antibody-mediated mechanisms during some part of the pathogenesis
such as during replication in extracellular spaces or when spreading through
extracellular fluids. The majoritymajority of the licensed vaccines produce serum
antibody titers that correlate with the level of protection induced by the vaccine [15].

1.4.2 Cellular immune responses

Although intracellular pathogens are susceptible to humoral responses during
the brief time they spend in the extracellular spaces, once they have entered into
cells the only way to resolve infection is by destroying the infected cells. The
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elimination of infected cells without affecting the healthy cells requires cell-mediated
immune responses. A cell-mediated immune response is generated when naïve
CD8+/CD4+ T-cells come into contact with mature, activated antigen-presenting cells
(APCs) in the lymphoid organs. T-cells are activated only when the APC is presenting
an antigen specific to the T-cell receptor (TCR) in the context of major
histocompatibility complex (MHC) molecules and a co-stimulatory molecule. Once
activated, naïve T-cells expand rapidly and differentiate into effector T-cells that can
resolve the infection. Effector cytotoxic CD8+ T cells (CTLs) recognize infected cells
and kill them by releasing several cytolytic molecules. Effector Th1 type CD4 T-cells
activate other antigen-presenting cells (APCs) and B-cells, Th17 type effector cells
recruit neutrophils to the site of infection, and Th2 type effector cells recruit
eosinophils, basophils and mast cells against pathogens such as helminths. Upon
resolution of infection, most of the effector T cells undergo apoptosis, while a small
population differentiates into long lived memory cells that can protect from reinfection.

Currently, almost all of the licensed vaccines utilize humoral responses as a
correlate of protection. However, it has become well known that humoral responses
are a poor correlate for many intracellular infections, and so many studies have been
conducted to better characterize cell-mediated immune responses. As of now,
measurements of antigen specificity of T-cells and T-cell functional responses to ex
vivo restimulation with antigen remain as the best correlates of protection.
1.5 Dendritic cells
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Antigen processing and presentation to naïve T-cells in the context of MHC I
and MHC II molecules is necessary for the generation of adaptive immune
responses. This is a job that can only be carried out by APCs – dendritic cells (DCs),
macrophages and B-cells. Of these, only DCs are specialized APCs while the other
two cell types participate in other functions of the immune system. DCs, often referred
to as the most professional APCs, can bind 30-200 times more antigen and are also
up to 1000-fold more efficient at activating T-cells than macrophages and B-cells [16].
Given that DCs are the most potent APCs, the type of immune response (proinflammatory or tolerant) generated after an infection or immunization depends on
the type of antigen, DC and the microenvironment during antigen uptake and
presentation.

1.5.1 DC subsets

DCs are a heterogeneous population of cells with a distinct shape consisting of
stellate cytoplasmic projections, which give them with a large surface area for antigen
capture and presentation [17]. In mice and humans, all steady state DCs originate
from hematopoietic precursors of myeloid or lymphoid pathways. Based on the origin,
phenotype and function, DCs can be classified into five subsets: conventional DCs
(cDCs 1 and 2), plasmacytoid DCs (pDCs), Langerhans cells (LCs), and monocytederived DCs (moDCs).

Both murine and human cDCs are CD11c+ MHC II+ cells that can be further
differentiated into CD8α+ (cDC1) or CD4+ (cDC2) cells in mice and CD1c+ (cDC1)
or CD141+ (cDC2) cells in humans. Both murine and human cDC1 cells express high
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level proteins required for cross-presentation and have the capacity to produce typeI IFN and IL-12 (p70), which gives them the ability to activate CD8+ T cells and prime
Th1 helper T-cells [18, 19]. In contrast, cDC2 cells in humans and mice polarize CD4+
T cells to Th2 and Th17 types.

The pDCs in humans and mice are broadly distributed throughout the body and
express CD11c, B220, SiglecH, and BST2 in mice versus CD123, BDCA-2 and
BDCA-4 in humans. pDCs have a high capacity to produce type-I IFN in response to
viral stimuli and play an important role in controlling the progress of viral infections.
Murine LCs express langerin (DC207) whereas human LCs are identified as
langerin+ DEC205+ CD1ahi CD11clo cells. The role of LCs in mice seems to be
adaptable and is dictated by the microenvironment. In steady state, murine epidermal
LCs continuously internalize and process antigens to induce tolerance, whereas
during inflammation they produce IL-23, IL-6 and IL-1β, which drive Th17
polarization. In humans, LCs are known to be efficient at cross-presentation to naïve
CD8

T-cells

and

secrete

IL-15

which

promotes

differentiation

of

granzymeB+/perforin+ CTLs [20]. MoDCs are a special type of DCs that are
produced from monocytes during inflammation. MoDCs predominantly drive Th1 and
Th17 type immune responses by producing IL-12 or IL-23.

1.5.2 Antigen uptake

DCs are abundantly located throughout the body at strategic locations like body
barriers (under the epithelium at mucosal surfaces) and organ entry ports [21, 22].
DCs continuously sample the surrounding environment for both self and non-self
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antigens using their dendritic appendages and induce immune tolerance or protective
responses, depending on the nature of antigen (self or non-self). Immature DCs are
very efficient at internalizing antigens from the environment using various endocytic
pathways, like macropinocytosis for the uptake of solutes and nutrients and
phagocytosis for the uptake of pathogens, apoptotic or dead cells, and large
particulate antigens. DCs also have highly specialized receptors like C-type lectin
receptors (CLRs), scavenger receptors (SRs) and Fc receptors (FcRs) on the cell
surface to capture and internalize antigens via receptor-mediated endocytosis. Upon
internalization, the antigen is then processed and presented to T-cells in the context
of MHC molecules.

1.5.3 DC Maturation and migration

The nature of the immune response generated towards an antigen depends
upon the maturation status of the presenting DC. On the one hand, antigen
presentation by immature DCs leads to T-cell anergy and immune tolerance [23, 24].
On the other hand, presentation by mature, activated DCs leads to T-cell activation
and an inflammatory response. DCs express several pattern recognition receptors
(PRRs), like Toll-like receptors (TLRs), NOD-like receptors (NLRs), RIG-1-like
receptors (RLRs) and CLRs, that can recognize pathogen-associated molecular
patterns (PAMPs) and damage associated molecular patterns (DAMPs), and
triggering of these receptors leads to the activation of DCs. Activation of DCs can
also be caused by triggering of FcR by immune complexes or CD40 by CD40L on
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CD4+ T-cells or by inflammatory cytokines like TNFα, IL-1 and PGE2, secreted as a
response to pathogenic infection.

Activation induces several changes in the expression of genes in DCs, leading
to secretion of chemokines and cytokines that can recruit other immune cells [25]. It
also leads to cytoskeletal rearrangement, downregulation of CCR1, CCR5 and
CCR6, and upregulation of CCR7, which allows their migration to lymph nodes [26].
Importantly, activation leads to redistribution of MHC and co-stimulatory molecules
(CD80, CD86 and CD40) to the surface of DCs which results in improved T-cell
activation [27].

1.5.4 Antigen processing and presentation

Typically, peptides derived from the degradation of cytosolic proteins by
proteases are transported into the endoplasmic reticulum by transporters associated
with antigen processing (TAP), where they are further processed by the ER
aminopeptidase associated with antigen processing (ERAAP) [28], then loaded onto
MHC I molecules and presented on the DC cell surface to CD8+ T-cells. Exogenous
antigens upon internalization are translocated from the phagosomes into the cytosol,
ubiquitinated and degraded into peptides by the proteasome. These peptides are
then transported into the ER or back into the same phagosomes, which have acquired
TAP and MHC I loading machinery by fusing with the ER, where they are loaded onto
MHC I molecules, transported to the cell surface and presented to CD8+ T-cells in a
process known as cross-presentation [29, 30].
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In contrast to peptide loading of MHC I molecules, loading of MHC II molecules
occurs only in the late stage phagolysosomes. Phagosomes containing exogenous
antigens or endogenous antigens (taken up during autophagy) fuse with lysosomes
containing

proteases

that

degrade

the

antigens

into

peptides.

These

phagolysosomes then fuse with ER vesicles containing the MHC II loading machinery
where they load the peptide onto MHC II molecules and transport them to the cell
surface to be presented to CD4+ T-cells.
1.6 Targeting antigen to dendritic cells for improving vaccine efficacy

Given the important role DCs play in coordinating adaptive immune responses,
targeting the antigen to DCs would potentially improve the immune responses
generated. So far, researchers have tried to target antigen to DCs in two ways: (i) by
administering vaccines in a way that they accumulate in DC-rich areas and (ii) by
targeting the receptors on DCs to mediate internalization and increase immune
responses.

1.6.1 Administration-based targeting

Simplest way of getting a vaccine to DC-rich areas is to directly inject the
vaccine into lymph nodes. Intranodal immunization with lentiviral vectors encoding
tumor-associated antigens or mRNA resulted in a strong CD8+ T-cell response when
compared to subcutaneous delivery [31, 32]. Another way of reaching lymph nodes is
to administer the vaccine near a lymph node so that the vaccine drains into the lymph
node. Intradermal delivery of antigens conjugated to nanoparticles (NPs) has been
shown to allow the antigens to drain efficiently into lymph nodes, resulting in an
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increase in antigen-specific immune responses [33, 34]. However, care must be taken
while formulating the vaccine so that the vaccine does not form a depot at the injection
site, which might lead to exhausted T-cell responses and reduce vaccine efficacy [3537].

1.6.2 Targeting DC receptors

DCs express several endocytic cell surface receptors that can be used as
targets for vaccine delivery (Table 1.2). So far, numerous DC-targeting vaccines have
been evaluated in pre-clinical and clinical stages (Table 1.3). Mostly, five receptor
families have been evaluated for DC targeting: CLRs, integrins, Fcγ receptors, MHC
II molecules and stimulatory receptors. Of these, CLRs are the most extensively
studied receptors. CLRs contain carbohydrate recognition domains (CRDs) that bind
to sugars in calcium-dependent manner. CLRs have the ability to internalize
glycosylated antigens, resulting in antigen processing and presenting in the context of
MHC molecules and making them an attractive target for vaccine delivery. Amongst
CLRs, macrophage mannose receptor (CD206), DEC-205, and DC-SIGN are the
most examined candidates for DC targeting.

1.6.2.1 Macrophage mannose receptor

CD206 is a type I CLR, which upon ligand binding is internalized through
clathrin-coated vesicles and recycled through the early endosomes. CD206-mediated
endocytosis of antigens has been shown to result in antigen presentation in the
context of both MHC I and II molecules. It has been demonstrated that immunization
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with mannan-conjugated MUC1 induces both Th1 and Th2 type immune responses
based on the type of mannan. MUC-1 conjugated to oxidized mannan was shown to
be 1000 times more efficient at generating antigen-specific CTL and Th1 responses
when compared to MUC1 conjugated to reduced mannan, which generated Th2 type
responses [38]. Coating of cationic liposomes containing HIV-1 DNA with mannan was
also shown to induce HIV-specific CTL responses and significantly enhanced Th1 type
immune responses as seen by antibody isotyping and cytokine secretions [39]. It has
also been demonstrated that targeting CD206 using a fusion protein of human antiCD206 mAb and melanoma-associated antigen pmel17 or model antigen ovalbumin
(OVA) generates potent antigen-specific CTLs [40, 41].

1.6.2.2 DEC205

Unlike CD206, DEC205 (CD205) is recycled through late endosomes that are
rich in MHC II molecules; because of this, antigens internalized through DEC205
mediated endocytosis are efficiently presented through MHC II molecules [42].
However, the DEC205 endocytic pathway is non-stimulatory and does not activate
DCs, which results in the induction of T-cell tolerance [43, 44]. Therefore, in order to
generate antigen-specific immunity, immunostimulatory adjuvants have to be
included in DEC205-targeting vaccines. Thus far, DEC205-targeted vaccines have
used HB290 single chain antibody (scFv) as a targeting moiety. Immunization with
scFv-coated liposomes containing OVA or OVA peptide antigens were found to
generate potent OVA-specific CTL responses that reduced growth of B16-OVA
tumors in mice. Protection was depended on the concurrent delivery of OVA and an
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adjuvant (IFN-γ or LPS) [44]. Also, immunization of mice with OVA conjugated to antiDEC205 mAb and anti-CD40 mAb protected against mucosal challenge[45].

1.6.2.3 Dendritic cell-specific ICAM-grabbing non-integrin (DC-SIGN)

DC-SIGN is a type II CLR that is primarily expressed on immature DCs; it
recognizes various pathogens such as EbolaEbola, herpes and HIV viruses. Like
DEC205, DC-SIGN-mediated endocytosis is routed through late endosomes where
the antigen is loaded onto MHC II molecules and presented to CD4+ T-cells [46].
Targeting antigen to DC-SIGN using anti-DC-SIGN mAb was shown to induce
proliferation in antigen-specific T-cells at a 100-fold lower concentration than nontargeted antigen [47]. Additionally, glycoliposomes modified with the glycan Lewis
(Le)(X), which is highly specific for DC-SIGN, were preferentially internalized by
human monocyte-derived DCs and also induced antigen-specific CD8+ T-cell
responses when the glycoliposomes were loaded with gp100 tumor antigen and the
adjuvant MPLA [48].

1.7 Immunomodulatory properties of C5a

The complement system is an important part of innate immunity, which plays
an integral role in the defense against invading pathogens. Activation of complement
system in response to pathogens, immune complexes, or injured tissue results in a
series of events that includes release of several biologically active peptide fragments
called anaphylatoxins, C3a, C4a and C5a, that have diverse biological functions [49].
Of the three anaphylatoxins, C5a is the most potent and binds to at least two seven-
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transmembrane receptors, C5aR and C5L2 that are expressed on multiple cell types
especially immune cells like DCs, macrophages, neutrophils and T-cells. C5a has
several immunological functions including recruitment of inflammatory cells, increase
vascular permeability and induce smooth muscle contraction, mast cell and neutrophil
degranulation and various cytokines (Fig 1.2)[50-56]. Apart from its immunological
functions C5a has also been implicated in developmental biology, CNS development
and neurodegeneration, tissue regeneration and haematopoiesis[57]. C5a has also
been shown to enhance antigen-specific antibody responses, antigen-induced T-cell
proliferation[58, 59], provide costimulatory and survival signals to naïve CD4+ T-cells.
C5a also stimulates murine and human DCs resulting in the upregulation of MHC II,
CD80, CD86, CD40 and CD54, and secretion of Th1 polarizing cytokines [60-62]. In
contrast, hindering of C5aR signaling promoted Th2 type and regulatory T cell
responses[63], and impaired memory CD4+ T cell generation [64].

1.8 Development of EP54 and EP67

Given the immunostimulatory properties of C5a, its use as a vaccine adjuvant
has tremendous promise. However, its use in clinic is limited by the potential side
effects that arise due to its pleotropic properties. Therefore, it became necessary to
identify the effector fragment of C5a that has immunostimulatory properties but not
inflammatory properties for clinical use[65, 66].

Human C5a is a 74-amino acid peptide that consists of two domains, first, the
N-terminal core (C5a1-63) domain that is responsible C5aR recognition and binding
and second, the functional C-terminal domain (C5a64-74) which is necessary for
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inducing biological functions (fig 1.3) [67]. Peptide analogs of C-terminal region (C5a6574)

were demonstrated to induce several C5a-like biological effects which depended

on the peptide conformation[68]. This led to the hypothesis that conformationally
restricted C5a65-74 analogs would induce specific C5aR-mediated activities.
Examination of a large panel of analogs based on C5a 65-74 Y65,F67 (YSKKDMQLGR)
in which the backbone of MQLGR was restricted resulted in the discovery of EP54
(YSFKPMPLaR), which demonstrated significantly more potent ability to induce
smooth muscle contraction of human umbilical artery [66, 69-71], however, EP54 also
triggered the C5aR on PMNs inducing β-glucuronidase release. Further analoging of
EP54 by introducing N-methylation generated EP67, which demonstrated ~3000 fold
higher selectivity towards C5aR expressed on antigen presenting cells compared to
PMNs, in contrast, EP54 was only 34 fold more selective[66]. Furthermore, these
conformational features protect EP54 and EP67 from proteolytic degradation by
serum carboxy-peptidases.

1.8.1 Vaccine adjuvant properties of EP54 and EP67

Because of the potent immunostimulatory properties of EP54 and EP67,
several studies have investigated their ability as a vaccine adjuvant (Table 1.4) to
improve antigen-specific humoral and cellular immune responses. Immunization of
mice and rabbits with a B-cell epitope form MUC1 conjugated to N-terminal of EP54
generated high MUC1-specific antibody titers, with an isotype characteristic to Th1
type response in mice[67]. Also, EP54 conjugated to a T-cell epitope from hepatitis B
surface antigen was shown to generate CD8+ CTL responses in mice. In the same
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study, it was also shown that it necessary to conjugate the T-cell epitope to the Nterminus of EP54 using a protease labile linker to generate CTL responses[72].
Similarly, EP67-conjugated protein vaccines were also shown to generate Th1-type
humoral immune responses, furthermore, EP67 was demonstrated to generate higher
antibody responses and Th1-type isotype switching in aged mice which were not
observed when CpG or alum were used as adjuvants [73]. Recently, we have also
shown preliminary evidence that EP67 can be used as a mucosal adjuvant in mice[74].
It is important to note that EP54 and EP67 have been shown to increase uptake,
processing and presentation of the conjugated antigen by interacting with the C5aRs
present on APCs, while simultaneously inducing the release of Th1 type cytokines
making them effective dual purpose vaccine adjuvants[75].
1.9 Summary

In summary, targeting of antigen presenting cells, especially dendritic cells,
appears to be a promising strategy to improve the efficacy of vaccines against many
life-threatening diseases. Despite the tremendous progress, we have made in APC
targeted vaccines a successful human vaccine is yet to be developed. Therefore,
there is a need to research more ways to target antigen to APCs. Unlike, most vaccine
adjuvants EP67 is a host-derived dual purpose immunostimulant with the capacity to
simultaneously, target and activate APCs and has shown great potential as an
adjuvant. This dissertation is an effort to explore the ability of EP67 to deliver
encapsulated antigen to APCs and increase immune responses generated against
the encapsulated antigen.
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Figure1.1 Schematic representation of the different stages involved in the
induction and regulation of cell-mediated and humoral immune response
against pathogens.
Reproduced with permission from [15]
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Figure 1.2 Role of Complement C5a in host defense and homeostasis.
Reproduced with permission from [76]
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Figure 1.3. Structure of human C5a
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Table 1.1 – Overview of phenotypic and functional features of DC subtypes.
Adapted with permission from [77]
cDC1
cDC2
pDC
CD8α+/CD103+ CD4+ CD11b+ SiglecH+
DEC205+
BST2+
B220+

LC
Langerin+

Human
markers

CD141+
CD162hi
DEC205hi

CD1c+
CD11blo

CD123+
BDCA-2+
BDCA-4+

Langerin+
DEC205 CD1ahi

Functions

T H1
Crosspresentation

TH2 and TH17
Crosspresentation

IFNα/β and
IFNλ Humoral

Adaptable
MOUSE: Treg
or TH17
HUMAN: IL-15
promoting CTLs
+ Crosspresentation

Murine
markers

moDC
CD11b+
CD64
FcγRε and
Ly6c
CD11b+
CD1a+
CD24+
CD206+
CD16+
DC-SIGN
Highly
adaptable
(IL-12, IL23, TNFα,
and iNOS)
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Table 1.2: Summary of dendritic cell receptors targeted for vaccine
development. Adapted with permission from[78]
Receptor
1. Group 1 C-type lectin
receptors

1.1. Mannose receptor

Designation

Function

CD206

Expressed on macrophages and DCs. Binds to
mannan, mannose, fucose, glucose, maltose,
GlcNAc, lipoarabinomannan, cell wall of yeast,
viruses, and bacteria leading to
phagocytosis/endocytosis. Used to target
protein, peptides, DNA, dendrimers, liposomes,
and anti-MR antibodies for vaccine development
withTh1, Th2, CTL, and Ab responses induced.
Targeting antigens to MR using mannan has
been used in human clinical trials.

CD205
1.2. DEC205
Ly 75

Homologous to the mannose receptor.
Expressed on DCs and thymic epithelial cells.
Targeting induces an array of immune
responses.

2. Group 2 C-type lectin
receptors

2.1. Dendritic cell-specific
intercellular
adhesion molecule-3grabbing
nonintegrin (DC-SIGN

CD209
Clec4L

Expressed on immature DCs, macrophages
endothelial vascular cells, atherosclerotic
plaques, and lymphatic vessels, not on
placmacytoid DCs. Binds to mannan, mannose,
fucose, GlcNAc, GalNAc, yeast, lewis blood
group antigens Lex, HIV-1 gp120, Ebola virus,
hepatitis C virus, dengue virus, respiratory
syncytial virus, measles virus, Mycobacterium
tuberculosis, Leishmania amastigote,
Helicobacter pylori, Leishmania mexicana,
Schistosoma mansoni, Porphyromonas
gingivalis, Neisseria gonorrhoeae, Candida
albicans, house dust mite (Der p1), and dog
allergens (Can f1). Interacts with ICAM-3 and
ICAM-2. Targeting DC-SIGN using antigen
linked to anti-DC-SIGN antibodies, Manalpha-6
Man, lactoside, and Lewis oligosaccharide,
stimulates T-cell and/or antibody responses,
and has been studied as a potential receptor for
vaccine targeting. Eight murine homologs
identified, SIGN-R1 (CD209b) to SIGN-R8.
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Receptor

2.1.1. L-SIGN or DCSIGNR

2.1.2. Liver and lymph
node sinusoidal
cell type lectin (LSECtin)

2.1.3. C-type lectin
immune receptor
(CIRE)
(murine homologue of
DC-SIGN)

2.2. Langerin CD207

Designation

CD299
CD209L
Clec4M

Function
Expressed on liver sinusoidal cells, lymph
nodes, and endothelial vascular cells, but not on
DCs. Binds to HIV gp120, Man9GlcNAc2, HIV,
simian immunodeficiency virus, ebola virus,
hepatitis C virus, and respiratory syncytial virus.
Targeting L-SIGN with anti-L-SIGN antibodies
induces T-cell responses. Targeting L-SIGN
shows promise for the development of targeted
vaccines.

Clec4G

Expressed in liver, lymph nodes, sinusoidal
endothelial cells, DCs, and Kupffer cells. Binds
to N-acetyl-glucosamine, fucose, ebola virus,
filovirus glycoproteins, lymphocytic
choriomeningitis virus, S-protein of SARS
coronavirus, and to CD44, but not to mannose,
HIV, and hepatitis C. Coexpressed with DCSIGNR and CD23. Antibody or ligandmediated engagement of LSECtin activates
rapid internalization, indicating that LSECtin
may be a suitable receptor for targeting antiges
in the development of vaccination regimes.

CD209

Expressed by immature CD8− splenic DCs
(CD8−CD4+ and CD8−CD4−), on some
CD4+ DCs, plasmacytoid pre-DCs, and
not by, CD8+ DCs, macrophages, or
monocytes. It is a ligand for ICAM-3 and
binds to HIV. Polyanhydride nanoparticles
covalently linked to dimannose and lactose
matures DCs and are internalized by DCs.
CIRE shows promise as an appropriate
target for antigen delivery for improved
vaccine development.

Clec4K

Expressed on Langerhans cells, CD103+
DCs, and splenic CD8+ DCs. Binds to
mannose and internalizes mannose
residues into Birbeck granules, where
Langerin is expressed. Anti-Langerin
antibody targeting antigens to Langerin is
endocytozed in vitro and in vivo and
induces Th1 and antibody responses.
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Receptor

Designation

2.3. MGL
(human macrophage
galactose- and
N-acetylgalactosaminespecific C-type
lectin)

2.4. Dectin-1 or betaglucan receptor
(DC-associated C-type
lectin-1)

2.4.1. DNGR-1
(NK lectin group
receptor-1)

2.4.2. Myeloid inhibitory
C-type lectin
receptor (MICL)

Function
Expressed on macrophages, immature
DCs galactose, GalNAc, Tn antigen,
filoviruses, and gonorrhea. GalNAc
modified peptides to target MGL receptor
expressed on murine and human DCs,
which stimulates T-cell and antibody
responses, and this approach could be
used to design novel anticancer vaccines.

DCAL-1
Clec7A

Expressed on myeloid DCs, CD8−CD8−
DCs, dermal DCs, monocytes,
macrophages, neutrophils, T cells, B cells,
mast cells, eosinophils, and monocytes.
Binds to beta-glucan on yeast,
mycobacteria, plant cell walls,
Saccharomyces, Candida, Pneumocystis,
Coccidioides, Penicillium, and Aspergillus,
but not Cryptococcus fungal species, and
interacts with CD37. Anti-Dectin-1 and
anti-Dectin-2 antibodies linked to proteins
stimulate CD8+ and CD4+ T cells, and
immunization with beta-glycan modified
proteins induces CD4+ andTh17 bias
responses.

Clec9A

Expressed onmurine CD8+ DCs not on
CD4+ DCs, on CD11c+ DCs but not by
CD11c− cells (B cells, T cells, NK cells,
NKT cells, macrophages, and
granulocytes), on plasmacytoid DCs, and
on human
blood DCsBDCA-3+ DCs) and monocytes
(CD14+CD16−). Highly expressed on Flt3
ligand bone marrow derived CD8+ DCs.
Target for immune response induction.

Clec12A

Homologous to Dectin-1 and part of
Dectin-1 cluster. Also termed as CLL-1,
DCAL-2, and KLRL1. Expressed on
granulocytes, monocytes, macrophages, B
cells, CD8+ T cells in peripheral blood, and
DCs
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Receptor

2.4.3. C-type lectin-like
receptor 2
(CLEC2)

2.4.4. CLEC12B
(macrophage antigen H)

2.4.5. LOX-1
(Lectin-like receptor for
oxidized density
lipoprotein-1)

Designation

Function

Clec1B

Expressed on NK cells, monocytes,
granulocytes, platelets, megakaryocytes,
and liver sinusoidal epithelial cells. Binds
to HIV-1 and facilitates HIV-1 spread to
other cells and binds to snake venom
rhodocytin. Not much is known regarding
stimulating immune responses; however,
colocalization with DC-SIGN suggests that
it may have an immune stimulatory effect.

Clec21B

Part of the NK gene complex/dectin-1
cluster of C-type lectin receptors.
Expressed on macrophages, monocytes,
and DCs. Not much is known regarding its
function.

Clec8A

Part of the dectin-1 cluster of C-type lectin
receptors and scavenger receptor family.
Expressed on endothelial cells, smooth
muscle cells, platelets, fibroblasts, and
macrophages. Binds to Gram-positive and
Gram-negative bacteria, oxidized LDL
modified lipoproteins, phospholipids,
apoptotic cells, C-reactive protein, and heat
shock protein (HSP)-70. Targeting LOX-1
induces immune responses and is a
promising target for cancer immunotherapy.

2.5. DC immunoreceptor
subfamily
2.5.1. DC
immunoreceptor (DCIR)

2.5.2. Dectin-2
(or beta-glucan receptor)

Clec4A

DCAL-2
Clec6A

Expressed on plasmacytoid DCs, immature
and mature monocyte-derived DCs
monocytes, macrophages, and B cells.
Binds to TLR9. Targeting DCIR stimulates
immune responses especially CD8+ T cells.
Expressed on DCs, macrophages
neutrophils, and monocytes. Binds to
beta1,3 and beta1,6-linked glucans on
yeast, mycobacteria, and plant cell
walls. Targeting dectin-2 stimulates immune
responses in mice.
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Receptor
2.5.3. Blood DC antigen
(BDCA-2)

Designation
Clec4C

3. Scavenger receptors
3.1. Scavenger receptor
macrosialin, mucins, and
LOX-1. Targeting of
scavenger receptors
induces immune
responses in mice.
3.1.1. Scavenger
receptor class A

3.1.2. Scavenger
receptor class B
3.1.3. Scavenger
receptor class C

3.2. DCasialoglycoprotein
receptor (DC-ASGPR)

4. F4/80 receptor

4.1. FIRE

Function
Expressed on human blood DCs.
Targeting BDCA-2 suppresses IFNalpha/beta cytokine secretion.

Expressed on macrophages. Bind to
modified low density lipoproteins (LDL) by
oxidation (oxLDL) or acetylation (acLDL).
Bind to CD68, macrosialin, mucins, and
LOX-1. Targeting of scavenger receptors
induces immune responses in mice.
SR-A1
SR-A2

Expressed on macrophages as a trimer.
Members include SCARA1 (MSR1),
SCARA2 (MARCO), SCARA3,
SCARA4 (COLEC12), and SCARA5.

SR-B1

Consists of 2 transmembrane units.
Members include SCARB1, SCARB2, and
SCARB3 (CD36).

SR-B1

Consists of a transmembrane region in
which the N-terminus is located
extracellularly.
A lectin-like scavenger receptor.
Expressed on monocyte derived DCs
(CD14+CD34+), tonsillar interstitial-type
DCs, and granulocytes.
Targeting DC-ASGPR induces
suppressive responses.
Expression restricted to macrophages.
Murine homolog of the epidermal growth
factor-like module containing mucin-like
hormone receptor-1 protein encoded by
the EMR1 gene.
Expressed on CD8−CD4+ and CD8−CD4−
immature DCs, and weakly on monocytes
and macrophages. Targeting FIRE
stimulates immune responses in mice.
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Receptor
5. DC-specific
transmembrane protein
(DC-STAMP)

6. FcR

Designation

Function
Expressed on DCs and activated blood
DCs.
Targeting DC-STAMP results in
immunosuppressive responses in
some studies and in other studies
stimulates strong cellular responses.
Links humoral and cellular immune (Fc
Receptor) responses, links innate and
adaptive immune responses by binding
pathogens and immune complexes, and
stimulates T cells. Targeting FcR is a novel
vaccine strategy for stimulating immune
responses.
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Table 1.3: Summary of APC targeting studies. Adapted with permission from [77].
Targeting moiety

Injection

Effect

Ref.

DEC205
α-GalCer NP

fp

↑iNKT, ↓growth in B16F10, and
EG7-OVA (P + T)

[79]

Selected nucleic acid
aptamer

i.v.

↑CD8, ↓growth OVA-B16 tumor (T if
OT-I transfer)

[80]

Anti-CD11c and
DEC205 scFv coupled
to NP

i.v.

↑CD8, ↓growth OVA-B16 tumor (P)

[44]

mAb fused protein

s.c.

↑CD8, ↓growth OVA-B16 (P + T)

[45]

mAb fused protein

i.p.

↑CD8, ↑CD4, ↑humoral, and ↓growth
neu-expressing mammary tumor (P)

mAb fused protein

i.p.

↑cross-presentation, ↑CD4,
↑humoral, and ↓growth neuexpressing mammary tumor (P)

[83]

scFV modified
adenoviral vector

fp

↑T cell, ↑humoral (at low doses),
↓growth OVA-B16 (P) BUT better for
untargeted vectors

[84]

mAb fused protein

fp

↑CD8, ↓growth B16 pseudometastasis model (P + T)

[85]

Bacteriophage
displaying scFV

fp

↓growth B16F10 (Pro + Ther)

[86]

[81, 82]

mAb fused protein

s.c.

↑CD8, ↑CD4, and ↓growth B16
melanoma (P + T)

[87]

scFV fused to DNA
vaccine

i.m.

↑CD8, ↑humoral, long lasting
memory ↓growth ER2/neu+ D2F2/E2
breast tumor + spontaneous
mammary carcinomas (P + T)

[88]
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Targeting moiety
Phase I clinical trial with
CDX-1401 = human mAb
fused protein

Injection

Effect

Ref.

i.d.

Patients with advanced
malignancies: ↑cellular,
↑humoral (T)

[89]

Mannosylated NP

s.c.

↑TH1 cell, ↑humoral, and
↓growth B16F10 (P + T)

[90]

mAb fused to protein

s.c.

↑T cell, ↑humoral, and
↓growth B11-OVA (P)

[41]

Mannan coupled protein

i.p.

↑CD8, ↓growth P815
mastocytoma (T)

[91]

Mannose coupled
dendrimer

i.d.

↑CD8, ↑CD4, ↑humoral,
↓growth B16-OVA (P)

[92]

Mannosylated NP

s.c.

↓growth huErbB2+ renal
carcinoma cells (T)

[93]

[92]

DEC206

Mannan coated liposomeprotamine-DNA

U

↓growth E7+ TC-1 (P + T)

Mannosylated and/or
histidylated NP loaded with
mRNA

i.v.

↑CD8, ↓growth B16F10 (P)

Mannan or pullulan NP
complexed with protein

U

↑CD8, ↓growth
HER2+ tumors (P + T)

[96]

[94, 95]

D-mannose conjugated
lipid-core peptide system

s.c.

↓growth TC-1 HPV-16 tumor
(P)

[97]

Clinical trial with mannan
coupled protein

s.c.

↑humoral, less ↑CD8,
protection against
recurrence in breast cancer
patients

[98]
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Targeting moiety

Injection

Effect

Ref.

Two phase I studies with
CDX-1307 = hCG-β fused
to mAb

i.d. or i.v.

↑humoral and T cell with clinical
benefit in patients with
advanced epithelial
malignancies

[99]

↑CD8, ↑CD4, and ↓growth
transgenic adenocarcinoma,
E.G7-OVA and PSCAexpressing B16-F10 (P + T)

[100]

↓growth human Burkitt’s
lymphoma cell line in humanized
mice (P)

[101]

s.c.

↑CD8, ↓growth CT26 colon
carcinoma cells (P + T)

[102]

s.c.

↑CD8 and cross-priming,
↓growth E.G7 cells (P)

[103]

mAb coupled to peptide

s.c.

↑TH1, ↓growth MUC-1A2K/b+ MC38 (P + T)

[104]

mAb coupled to peptide

s.c.

↑CD8, ↓growth B16 lung pseudo
metastases (P + T)

[105]

i.p.

↑CD8, ↑CD4 (mixed TH1/TH2),
↑humoral, and ↓growth B16F10OVA (P + T)

[104]

DC-SIGN
LV pseudotyped with pointmutated Sindbis virus
glycoprotein

mAb coupled protein

IDLV pseudotyped with
engineered Sindbis virus
glycoprotein

i.d.

U

LOX-1
HSP70 fused to protein

CLEC9A

DCIR2
Anti-DCIR2 or antiDEC205 mAb coupled
protein
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Targeting moiety

Injection

Effect

Ref.

CD11c
Targeted lipopeptide

i.d.

↓growth for OVA: E.G7-OVA, for mWT1:
mWT1–1498 cells and for tumor lysate:
MHC-I- B16D8 melanoma (T)

[106]

Tumor-derived plasma
membrane vesicles
engrafted with two
CD11c binding
peptides

i.v.

↑CD8, ↑humoral, and ↓growth of
metastatic B16-OVA (T)

[107]

CD11b
Adenylate cyclase(CyaA-) based vector

Phase II study with
ProCervix = CyaAbased vector

i.p. vs.
↓growth OVA-B16 or E.G7-OVA versus
i.v. or i.d. TC-1 (P + T)

[108]

s.c.

Clinical phase I trial indicated good safety
and local tolerance at the highest dose, ↑T
+ ↑viral clearance + controlled HPV
recurrence

[109]

s.c.

↓growth E.G7 (P + T)

[110]

Fc γ receptor
IgG1-Fc tumor cells
HER2-Fc cDNA

i.m. + EP Mu: ↑T, ↓growth HER2+ D2F2/E2 cells (P)
Hu: in vitro cross-processing and ↑CD8+ T
cells from breast cancer patients

[111]

MHC-II
DNA loaded
dendrimer with
targeting peptide

s.c.

↑CD8, ↑humoral, ↓growth, strong for
B16OVA, and weak for gp70 BUT better
with EP (P) ↔ B16 with Trp2 (T)

[112]
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Targeting moiety

Injection

Effect

Ref.

LV pseudotyped with
scFv coupled to H
protein of measles
virus envelope

i.v.

↑CD4, ↑cytotoxic, and memory
CD8 BUT not to the same extent
as broad tropism LVs

[113]

LV pseudotyped with
scFV coupled to
murine leukemia virus
envelope

s.c.

↑CD8 mediated IFNγ secretion

[114]

DNA encoding antiMHC II and anti-CD40
scFv or chemokines
(MIP-1α, RANTES)
with scFV of idiotype

i.m. or i.d.
+ EP

↑CD8, ↑humoral, and ↓growth
Id+ tumors (P)

[115]

↑CD4, ↑CD8, ↑humoral +
↓growth B16-OVA (P)

[116]

BST2
Protein fused antiBST2 Ab

i.p.

CD40
CD40
PLGA-NP coated
with mAb

s.c.

↑CD8, ↑CD4 + ↓growth
B16-OVA (P + T)

[117]

CD40 targeted
adenoviral vector

i.p.

↑CD8, ↓growth RM-1PSMA model (T)

[118]

CD40L extracellular
domain to
adenoviral vector in
mice +
Clinical trial

i.d.

Mice: ↑CD8, ↓growth
B16F10 (T)
↑CD8 in melanomadraining sentinel lymph
nodes

[119]
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Targeting moiety

Inject
ion

Effect

Ref.

B7
↑CD8, ↑humoral, ↓growth
ErbB2+ renal cell carcinoma (T)

[120]

i.p.

↑CD8, ↑CD4, ↓growth
neu+ mammary tumor cell line
NT2.5 (P)

[121]

TLR9 targeting protein
(via DNA sequence)

i.d.

TH - independent ↑CD8 + ↓growth
E.G7-OVA (P + T)

[122]

TLR2 targeting lipid
moiety + epitopes

s.c.

↑CD8, ↑humoral + ↓growth B16OVA, and Lewis lung-OVA (P + T)

[123]

TLR5 targeted peptides
(via flagellin) engrafted
onto liposomes

i.v.

↑maturation of DCs, ↑CD8,
↑humoral, ↓growth B16, and P815
(P + T)

[124]

TLR4 targeting protein
(via fibronectin)

i.t. or
i.v.

↑CD8 with cure of established TC1 tumors
i.t.: in the absence of additional
ADJ
i.v.: when + ADJ or CPM + ADJ

[125]

↑CD8, ↓growth B16-OVA or B16.F10
(T)

[126]

Syngeneic epithelial
cells continuously
secreting CTLA-4-ErbB2
fusion vaccine

s.c.

Treml4, Ig superfamily member
mAb against Treml4

TLRs

TLR4 targeting protein
(via fibronectin) + antiCD40, TLR3 and TLR7
ligands

s.c.
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Targeting moiety

Injection

Effect

Ref.

Chemokine related
Fusion of chemokine
MCP3 or IP10 to
lymphoma-derived
scFv as protein or
DNA plasmid

s.c. or
i.d.

OVA with mAb or
chemokine ligand
XCL1 against XCR1

i.v.

↑humoral, ↓growth 38C-13
and A20 (P)

[127]

↑CD8, ↓growth E.G7 (P)

[128]

P: prophylactic, T: therapeutic, fp: footpad, i.v.: intravenous, s.c.: subcutaneous, i.p.:
intraperitoneal, i.m.: intramuscular, EP: electroporated, i.d.: intradermal, i.n.:
intranodal, i.t.: intratumoral, U: unknown, CPM: cyclophosphamide iNKT: induced
natural killer T cell.
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Table 1.4: Vaccine adjuvant properties of EP54 and EP67
Vaccine Construct

Route

Immune Response

Ref

Peptide epitope from MUC1
glycoprotein conjugated to EP54

i.p.

↑IgG2b, IgG2c and IgM
Abs

[67]

CTL peptide epitope derived from
Hepatitis B surface Antigen
(HBsAg) conjugated to EP54

s.c

Ag-specific CD8+ CTL
responses against murine
P815S target cells

[72]

Nicotine hapten conjugated to
EP54

i.p.

Nicotine-specific Abs

[129]

Methamphetamine (meth) hapten
conjugated to EP54

s.c /i.p.

Meth-specific Abs in sera

[130]

OVA conjugated to EP67

i.p.

[75]

OVA conjugated to EP67

i.p.

OVA-specific Th1-like Ab
class switch and OVAspecific proliferative
responses in splenocytes
↑ Ag-specific humoral

rPrp1,a protein from cell wall of
coccidioides conjugated to EP67

i.p.

↑ humoral responses
compared to alum and
CpG

[73]

Peptide epitope derived from gp70
glycoprotein conjugated to EP54
and EP67

s.c

↑ CTL responses and
↓RAW117-H10 growth

[131]

Live spores of attenuated vaccine
strain of Coccidioides posadasii
conjugated to EP67

s.c

↑ IgG1, IgG2a, Th1, and
Th17 immune responses

[132]

CTL peptide epitopes from MCMV
PP89 and M84 conjugated to EP67

i.n.

↑ CTL responses
↓ MCMV titers

[74]

[73]
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CHAPTER 2

Hypothesis and Specific Aims
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2.1 Hypothesis

Antigen presentation by APCs to T-cells is the bridge between innate and
adaptive immune systems and dendritic cells as the most professional antigen
presenting cells play a central role in shaping the immune response. Therefore, many
strategies have been explored to harness DCs and other APCs to improve vaccine
efficacy, of these in vivo targeting of APCs using ligands and antibodies against
several APC surface receptors has shown promise in preclinical studies. However,
most of these studies have focused on PRRs, which recognize foreign antigens, as
the targets for antigen delivery and have ignored the complement receptors, which
respond to molecules produced by the host complement system. EP67 is a hostderived decapeptide, based on complement component 5a (C5a), that selectively
binds to the C5a receptor (C5aR/CD88) on APCs, resulting in their activation and
subsequent increase in processing and presentation of conjugated antigen.

The primary objective of this work is to develop C5aR-targeted PLGA
nanoparticles to improve immune responses against the encapsulated antigen, using
EP67 as the targeting moiety. The central hypothesis of this work is that surface
modification of PLGA nanoparticles encapsulating model antigen ovalbumin with
EP67 can target the nanoparticles to APCs, and generate efficacious immune
responses against the encapsulated antigen. The hypothesis has been tested through
the following specific aims.
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2.2 Specific Aims
2.2.1 Specific Aim-1 – Develop C5aR-targeted PLGA nanoparticles by first
functionalizing the surface of nanoparticles with PLLA-PEG-MAL linker and then
conjugating EP67 to the particles.
2.2.2 Specific Aim -2 – To determine the effect of surface modification of PLGA
nanoparticles with EP67 on antigen presentation by bone marrow-derived dendritic
cells in vitro.
2.2.3 Specific Aim – 3 – To determine the efficacy of respiratory immunization with
EP67 surface-modified nanoparticles to protect against primary respiratory infection
with Listeria monocytogenes expressing ovalbumin and to evaluate the immune
responses generated.
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CHAPTER 3

Materials and Methods
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3.1 Peptides

CGRR-EP67 (CGRR-YSFKDMP[MeL]aR) [70] and inactive scrambled CGRRscEP67 (CGRR-M[MeL]RYKPaFDS) [75] were synthesized by standard Fmoc (9fluorenyl-methoxycarbonyl) solid-phase methods on a pre-loaded Arg or Ser Wang
resin, respectively, by sequential coupling of the HBTU (2-(1Hbenzotriazole-1-yl1,1,3,3-tetramethyluronium hexafluorophosphate) esters of each amino acid as
described [66]. Peptides were cleaved from the resin by acidolysis with TFA
(trifluoroacetic acid) containing phenol [5% v/v], water [2% v/v], and triisopropylsilane
[2.5% v/v] as scavengers. Cleaved peptides were purified by analytical and
preparative reverse-phase HPLC, with C18-bonded silica columns using 0.1% TFA
(dH2O containing TFA [0.1% v/v]) as the running buffer (solvent B) and 0.1% TFAcontaining acetonitrile [60% v/v] (solvent B) as the eluent, and lyophilized.
3.2 Encapsulation of ovalbumin in biodegradable surface-modified PLGA
nanoparticles

Model antigen ovalbumin (OVA; Sigma-Aldrich) was purified by passing
through a Detox-GelTM endotoxin removal column (Thermo Scientific) and conjugated
to fluorescein isothiocyanate (FITC-OVA) before encapsulating in biodegradable
maleimide-functionalized nanoparticles (NP) at 10 wt% theoretical loading using a
modified double-emulsification / solvent evaporation (ESE) method [133, 134]. The
primary water-oil emulsion (W 1/O) was formed by adding an endotoxin-free “water”
solution of OVA in PBS (50 mg/mL; 0.2mL) drop-wise to a vortexing (500 RPM)
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dichloromethane (DCM) “oil” solution containing ester-terminated 50:50 poly D,Llactic-co-glycolic acid (PLGA 50:50; research grade; inherent viscosity 0.58 dL/g;
Lactel Pelham, AL; 50 mg / mL DCM; 2 mL) in an 8 mL scintillation glass vial and
sonicated on ice for 30 sec (pulse time - 10 sec; interval – 2 sec) at 70% amplitude
(Misonix Sonicator 3000 w/ model 419 tapered microtip horn with 0.125 in. diameter
tip). The W 1/O emulsion was immediately transferred dropwise to a vortexing PVA
solution (5% v/v polyvinyl alcohol [70% hydrolyzed; 30,000 -70,000 Da; Sigma-Aldrich]
in dH2O; 8 mL) in a 20-mL scintillation glass vial and sonicated to form the secondary
water-oil-water emulsion (W 1/O/W 2). The secondary emulsion was then transferred to
a fresh 20-mL scintillation glass vial and the NPs were surface-functionalized with
maleimide by adding a DCM solution containing the diblock copolymer poly L-lactic
acid – polyethylene glycol-maleimide (PLLA-PEG-MAL [10 kDa-2 kDa; Polyscitech];
20 mg/mL; 200 µL) to the emulsion. The emulsion was stirred (1000 rpm using a cross
shaped 9.5 × 4.7 mm, Teflon-coated, smooth stirring bar) for 18 h to fully remove
DCM. Hardened NP was pelleted (25,000 RCF, for 15 min at 4°C) then resuspended
and pelleted 3X using dH2O (50 mL) to remove residual PVA. Washed particles were
resuspended in dH2O (10 mL) in a pre-weighed 20-mL scintillation vial, flash frozen in
liquid N2, lyophilized for 48 h, and stored at -20°C until further use. Maleimidefunctionalized NP were then coated with CGRR-EP67/CGRR-scEP67 by adding
peptide solution in PBS (1.4 mg/mL; 0.5 mL) to a suspension of NP in PBS (2 mg/mL;
5 mL) in an 8 mL scintillation glass vial and stirring for 12 h (1000 rpm; cross-shaped
9.5 × 4.7 mm stirring bar). Surface modified NPs were then washed 3X in dH2O (50
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mL), resuspended in dH2O (10 mL), flash frozen in liquid N2, lyophilized for 48 h, and
stored at -20°C after sealing with parafilm.
3.3 OVA loading in PLGA particles

OVA loading was determined as described with modification [135]. Particles
(~10 mg) were allowed to equilibrate to r.t., added to DMSO (0.5 mL) in an 8-mL glass
vial, and incubated for 1 hr on with constant shaking. A solution of 0.05 M NaOH/0.5%
SDS in dH2O (5 mL) was added to the DMSO/particle solution and the entire solution
was stirred (400 RPM) in the capped vial overnight. The undissolved polymer was
pelleted (10,000 RCF, 10 min) and average OVA concentration in the supernatant
was determined by Pierce Micro BCA assay (Thermo Scientific) with OVA as the
standard and DMSO/0.05 N NaOH (0.05% SDS) as the diluent. For scEP67/EP67
surface modified NPs, maleimide-functionalized NPs were stirred for 12 h in PBS
(Section 2.1), washed, and lyophilized before determining OVA loading. Average µg
OVA/ mg formulation ± SD (n=3) was calculated by multiplying OVA concentration
from the assay by the volume of the sample (5.5 mL) and encapsulation efficiency
(EE%) was calculated as

EE% =

𝐴𝑠𝑠𝑎𝑦𝑒𝑑 µ𝑔 𝑂𝑉𝐴 ⁄𝑚𝑔 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑥 100
𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 µ𝑔 𝑂𝑉𝐴 ⁄𝑚𝑔 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠

3.4 Diameter and zeta potential of PLGA nanoparticles

Average hydrodynamic diameters and zeta-potentials ± SD (n=3 independent
samples from the same batch) of the particles were measured in dH 2O (0.5 mg/mL)
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at 25°C using a ZetaSizer Nano ZA (Malvern Instruments, Malvern, UK) equipped with
a He-Ne laser (λ = 633 nm) as the incident beam.
3.5 Generation and culture of bone marrow-derived dendritic cells.

Bone marrow-derived dendritic cells (BMDCs) were generated as described
[136, 137]. Femurs and tibiae were harvested from the hind limbs and cleaned by
scraping the muscle tissue using a sterile surgical scalpel (#15, Aspen Surgical,
Caledonia, MI). Bones were sterilized by placing in 70% ethanol for 5 min and rinsed
2X with RPMI-1640 medium. Bone marrow was exposed by cutting off the ends with
a sterile scissors and flushed out with complete RPMI (5 mL) (cRPMI; RPMI-1640
[Hyclone, Logan, UT] containing heat-inactivated fetal bovine serum [HI-FBS, 10%
v/v, Atlanta Biologicals, Atlanta, GA], L-glutamine [2 mM], sodium pyruvate [1 mM],
non-essential amino acids [0.1 mM], MEM vitamin solution [1X], penicillin G [100
U/mL], streptomycin sulfate [100 µg/mL], β-mercaptoethanol [50 µM]) using a 25gauge needle. Bone marrow pieces were broken down by gently pipetting the media
and the resulting cell suspension was passed through a 70 µm cell strainer (Becton
Dickinson, Franklin Lakes, NJ). Cells were pelleted (400 RCF;10 min at 4°C),
supernatant discarded, and erythrocytes lysed by resuspending in RBC lysis buffer (5
mL, 5 min at RT, RBC lysis buffer: 155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA).
Bone marrow cells were then washed 2X with RPMI-1640, and cultured in 100 mm
petri dishes (4 × 106 cells/dish) containing BMDC media (cRPMI supplemented with
rmGM-CSF [20 ng/mL, Peprotech, Rocky Hill, NJ]). On day 3, fresh BMDC media (10
mL) was added to the dishes. On day 6,six half of the media was collected, cells were
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pelleted, resuspended in BMDC media (10 mL) and added back to the dishes. BMDCs
were collected on day 8 and used for further experiments.
3.6 Internalization of nanoparticles by BMDCs
Internalization of NPs by BMDCs was measured by culturing BMDCs (4 x 10 5
cells/well; 24-well plate) in cRPMI (1 mL) containing FITC-OVA encapsulated,
uncoated NP [NP(FITC-OVA); 20 µg], FITC-OVA encapsulated NP surface modified
with scrambled EP67 [scEP67-NP(FITC-OVA); 20 µg] or EP67 [EP67-NP(FITC-OVA);
20 µg] for 2 h at 37 oC/5% CO2. To control for adsorption of NP onto the cell surface,
BMDCs were allowed to equilibrate at 4 oC for one h, then treated with NP and
incubated for 2 h at 4 oC. Cells were washed 3X in PBS (1 mL), stained with Zombie
Yellow, anti-mouse CD11c-PE Cy5 (clone N418, eBioscience, San Diego, CA) and
analyzed by flow cytometry.
3.7 Activation of BMDCs

Activation of BMDCs by NPs was measured by culturing BMDCs (4 x 10 5
cells/well; 24-well plate) in cRPMI (1 mL) containing NP(OVA) [100 µg], scEP67NP(OVA) [100 µg] or EP67-NP(OVA) [100 µg] for 24 h at 37 oC/5% CO2. Cells were
then washed 3X in PBS (1 mL), resuspended in sterile PBS (0.1 mL) containing
Zombie Yellow (1 µL, BioLegend), incubated at r.t. for 20 min in the dark, FACS Stain
Buffer (0.1 mL) was then added and cells were pelleted (500 RCF, 4°C, 5 min.).
Supernatants were aspirated and Fc receptors were blocked by resuspending in
FACS Stain Buffer (0.1 mL/well) containing mouse BD Fc Block (1 µg / 10 6 cells), and
incubating on ice for 20 min. FACS Stain Buffer (0.1 mL) was then added and cells
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were pelleted (500 RCF, 4°C, 5 min.). Cell surfaces were stained for activation
markers by resuspending the cells in FACS Stain Buffer (50 μL) containing half the
manufacturer’s suggested amount of PE-Cy5 Anti-Mouse CD11c [Clone N418]
(eBioscience), PE Anti-Mouse MHC-II [Clone M5/114.15.2] (Miltenyi), FITC AntiMouse CD80 [Clone 16-10A1] (Miltenyi), APC Anti-Mouse CD86 [Clone PO3.3]
(Miltenyi), then incubating on ice in the dark for 30 min. FACS Stain Buffer (0.15 mL)
was then added and cells were pelleted (500 RCF, 4°C, 5 min.). Cells were then fixed
by resuspending cells in Fixation Buffer (0.1 mL/well; BioLegend), and incubating on
ice for 20 min. Cells were then prepared for flow cytometry by washing in FACS Stain
Buffer (0.2 ml) (3X).

Cells were analyzed on a BD LSR II flow cytometer (Becton and Dickinson, La Jolla,
CA) with BD High Throughput Sampler. Flow cytometer was compensated using
single-stained cells, and thea maximum number of events were acquired and
analyzed by FlowJo software (Tree Star, Ashland, OR, USA).
3.8 Detection of antigen presentation by BMDCs
Antigen presentation of OVA epitopes (OVA257–264 /SIINFEKL – H-2Kb peptide
ligand; OVA323-339 /I-Ab peptide ligand) by BMDCs was measured by T-cell hybridoma
assay using OVA responsive T-cell hybridomas CD8OVA1.3 (OVA257–264) and DOBW
(OVA323-339) (kindly donated by C.V Harding, Case Western Reserve University) [138,
139]. Day 8 BMDCs (4 x 105 cells/well; 24-well plate) were cultured in cRPMI (1 mL)
containing NP(OVA) [100 µg], scEP67-NP(OVA) [100 µg] or EP67-NP(OVA) [100 µg]
for 2 h at 37 oC/5% CO2. BMDCs were then washed 2X in PBS (1 mL) and co-cultured
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with equal number of CD8OVA1.3 or DOBW cells (5 x 10 4 cells/well; 96-well plate) in
D10F media (0.2 mL) (DMEM/High Glucose [Hyclone, Logan, UT] containing HI-FBS
[10% v/v], penicillin/streptomycin [100 U/ml], sodium pyruvate [1 mM], HEPES [10
mM], and 2-mercaptoethanol [0.5 mM]) for 18 h at 37 oC/5% CO2[140]. Cells were
then pelleted (2000 RCF; 10 min; 4 oC), and supernatants collected and stored at -80
C until analyzed for secreted IL-2 by ELISA (Mouse IL-2 ELISA MAX™ Standard,
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BioLegend) per manufacturer’s instructions.
3.9 Respiratory Immunization

All animal procedures were approved by University of Nebraska Medical Center
Institutional Animal Care and Use Committee. Naïve female C57BL6/NHsd mice (4
weeks old, Envigo) were housed under pathogen-free conditions and allowed to
acclimatize for at least one week before experiments. Animals were immunized with
sterile PBS (50 µL) or sterile PBS containing NP-OVA or EP67 NP-OVA (25 µg OVA
equivalent) on days 0 and seven by intranasal instillation, which is expected to deliver
the vaccine to entire respiratory tract and lungs[141, 142]. For intranasal instillation,
mice were anesthetized with Ketamine/Xylazine cocktail (105/5 mg/kg, I.P), held
upright and the vaccine was administered by both nostrils using a 200 µL micropipette.
3.10 LM-OVA respiratory challenge and quantitation of bacterial burden.

Recombinant Listeria monocytogenes expressing ovalbumin (LM-OVA) (kindly
donated by John T. Harty, University of Iowa) [143] was cultured in Tryptic soy broth
(Sigma-Aldrich) containing streptomycin sulfate (50 µg/mL) at 37 oC in a shaking
incubator (150 RPM) for 24 h. Sterile glycerol (1 mL; 80% v/v) was added to LM-OVA
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culture (9 mL), aliquoted into cryovials (1 mL) and stored at -80 oC until the day of
infection. LM-OVA titers in one of the frozen stocks were determined one day before
immunization.

At fourteen days post-immunization (Day 21), animals were infected with a sublethal dose of LM-OVA (2 × 107 CFU) in the same method as vaccines. Three days
post-infection (Day 24) animals were sacrificed and the organs were harvested (lungs,
liver and spleen). Bacterial burden in the organs was determined by homogenizing the
organs in cRPMI (1 mL) using a hand-held homogenizer and 10-fold serial dilutions
were prepared using D-PBS as diluent. The dilutions (20 µL) were pipetted onto a
TSB-agar plate (100 mm; MIDSCI), the plates were allowed to dry in a sterile hood
and incubated for 24 h at 37 oC[144]. The number of bacterial colonies was then
counted by eye. Average LM-OVA titers/g of tissue was calculated as
𝐿𝑀 − 𝑂𝑉𝐴 𝐶𝐹𝑈
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 ℎ𝑜𝑚𝑜𝑔𝑒𝑛𝑎𝑡𝑒 (𝑚𝐿)
= 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠× 𝐷𝐹 ×
𝑔
𝑠𝑎𝑚𝑝𝑙𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑚𝐿)×𝑜𝑟𝑔𝑎𝑛 𝑤𝑒𝑖𝑔ℎ𝑡

Where the number of colonies was taken from the highest dilution where 5 to 50
colonies were observed, DF was the selected dilution factor, the sample volume is the
volume plated (0.02 mL) and volume of homogenate = [volume of cRPMI (1 mL) +
organ weight].
3.11 Preparation of lung lymphocytes and splenocytes
Fourteen days’ post-immunization (Day 21), on the same day as respiratory
challenge with LM-OVA, mice were euthanized, and the lungs were perfused with
sterile DPBS (5 mL) via right ventricle of the heart and harvested. Lungs were then
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dissected into small pieces using a sterile scissors and transferred to a sterile C-Tube
(Miltenyi) containing cRPMI (5 mL) with collagenase IV (2 mg/mL; Worthington
Enzymes). Lungs were then homogenized using Miltenyi tissue dissociator
(“m_lung_01” setting) and incubated for 1 h at 37° C in a shaking incubator (200 RPM,
Vortemp). Lungs were homogenized again on the tissue dissociator (“m_lung_01”
setting) and a single cell suspension was obtained by passing the cells through a
sterile 40 µm cell strainer. Cells were then pelleted (400 RCF, 4°C, 5 min), supernatant
decanted and resuspended in cRPMI (5 mL) in a sterile 15 mL conical tube (BD
Falcon). Lympholyte-M solution (5 mL; Cedarlane Labs) was under-layed below the
cell suspension using a sterile Pasteur pipette and centrifuged (1500 RCF, 20 mins,
RT, no brakes) to separate lymphocytes. Lymphocytes at the interphase were
collected, washed 1X with sterile PBS, resuspended in cRPMI and stored on ice until
used.

To prepare single cell suspensions of splenocytes, spleens were first
homogenized using a tissue dissociator (“m_spleen_01” setting) in cRPMI (5 mL),
passed through a 70 µm cell strainer and diluted with sterile DPBS (45 mL). Cells were
then pelleted (500 RCF, 4°C, 10 min), the supernatant was decanted, and the cells
were resuspended in RBC lysis buffer (4 mL) and incubated for 5-7 min at RT. Cells
were then passed through a 40 µm cell strainer, washed twice with D-PBS (50 mL),
resuspended in cRPMI and stored on ice until used. Percent viability and total live cell
counts were determined by trypan blue exclusion using a Cellometer Auto T4 cell
counter (Nexcelom Biosciences).
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3.12 Surface phenotyping of antigen-specific T-cells

The surface phenotype of antigen specific T-cells was determined at 14 days
post-immunization (Day 21) by flow cytometry. Lung lymphocytes and splenocytes
were isolated and plated in 96-well plates (106 cells/0.1 mL/well). Cells were washed
twice by pelleting (400 RCF, 4°C, 5 min.) and resuspending in DPBS (0.2 mL). Dead
cells were then stained by incubating the cells in DPBS (0.1 mL) containing Zombie
NIR dye (1 µL/106 cells), and the cells were incubated for 20 min at RT in dark. Cells
were then washed once with BD Stain Buffer (0.1 mL) and Fc receptors were blocked
by incubating in BD Stain Buffer (0.1 mL) containing mouse BD Fc Block (1µg / 106
cells) and incubating on ice for 20 min. Cells were washed with BD Stain Buffer (0.1
mL) and stained with OVA tetramers by incubating with BD Stain Buffer (50 µL)
containing MHC Class-I Tetramers-BV421 (NIH Tetramer core - H-2Kb / SIINFEKL)
or MHC Class-II Tetramers-BV421 (NIH Tetramer core-I-Ab / HAAHAEINEA) (1 µg/
106 cells) for 30 mins at 37 oC in the dark. Cells were then washed with BD Stain Buffer
(0.15 mL) and stained with cell surface markers by incubating in BD Stain Buffer (50
µL) containing half the manufacturer’s suggested amount of FITC Anti-Mouse CD8a
FITC (Clone 53-6.7; BioLegend) or Alexa flour 488 Anti-Mouse CD4 (Clone
GK1.5;BioLegend), PE Anti-Mouse CD127 (Clone A7R34;BioLegend), APC AntiMouse KLRG1 (Clone 2F1;BioLegend), PE/Dazzle Anti-Mouse CD62L (Clone MEL14;BioLegend) and PE/Cy5 Anti-Mouse CD44 (Clone IM7;BioLegend) on ice for 30
min in the dark. Cells were then washed in BD Stain Buffer (0.15 mL) and fixed by
incubating with Fixation Buffer (0.1 mL) on ice for 20 min. Cells were then washed
twice with BD Stain Buffer (0.2 mL), resuspended in BD Stain Buffer (0.2 mL) and
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analyzed on a BD LSR-II flow cytometer. Splenocytes from immunized animals were
used as single-stains for tetramers and BD CompBeads (Anti- Rat/Hamster Igκ) were
used as single-stains for all the other antibodies for compensation settings. Maximum
number of events from each sample were acquired and analyzed by FLowJo software
(Tree Star, Ashland, OR, USA).

3.13 Quantitation of cytokine secretion by epitope responsive splenocytes

The cytokine secretion profile of splenocytes harvested 14 days postimmunization was determined by re-stimulating cells (2 × 106 cells) ex vivo by
incubating

with

cRPMI

(0.4

mL)

containing

OVA

I-Ab

epitope

(ISQAVHAAHAEINEAGR; 10 µg/mL) in a 48-well plate for 48 h at 37 oC/5% CO2.
Supernatants were collected and stored in -80 oC freezer until analyzed, using a
multiplex assay (Mouse Th17 Magnetic Bead Panel, Millipore) per manufacturer’s
instructions. The concentration of cytokines was measured as median fluorescence
intensity (MFI) of at least 50 beads per cytokine. Standards were measured in
duplicates for seven concentrations including a blank control. Standard curves for
each

cytokine

were

(www.myassays.com).

plotted

using

a

five-parameter

logistic

curve

fit

51

CHAPTER 4

RESULTS
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Encapsulation of protective proteins or peptides in nanoparticles composed of
biodegradable poly (lactide-co-glycolic acid) polymers is a well-established platform
to improve efficacy of subunit vaccines by (i) protecting vaccines from enzymatic
degradation, (ii) increasing residence time at administration site, (iii) facilitating uptake
by APCs because of their particulate nature and, (iv) acting as an adjuvant that can
activate APCs. Moreover, the surface of nanoparticles can also be modified with
various ligands or antibodies that can target APCs to further improve vaccine efficacy.
Several studies have demonstrated that modifying the surface of nanoparticles with
ligands or antibodies targeting intracellular and extracellular pattern recognition
receptors (PRRs) such as Toll-like receptors (TLRs), C-type lectin receptors (CRRs)
and NOD-like receptors (NLRs) can induce humoral and cell-mediated immune
responses against encapsulated antigens.
In our previous studies, we have demonstrated that EP67, a host-derived
decapeptide based on complement component 5a (C5a) of the innate immune
system, acts as an immunostimulant and an adjuvant capable of generating Th1
biased humoral and cellular immune responses in mice against a covalently
conjugated peptide, protein or inactivated pathogens upon systemic administration. In
our recent studies, we have also shown that respiratory immunization with an EP67based vaccine composed of protective CD8+ T-cell epitopes from murine
cytomegalovirus (MCMV) protects against primary respiratory infection with MCMV
and increases the proportions of epitope-specific long-lived memory precursor effector
cells (MPEC) in the lungs and spleen compared to an inactive, scrambled EP67-
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conjugated CTL peptide vaccine and vehicle alone, suggesting that EP67 can act as
a mucosal adjuvant.
EP67 is expected to act as an adjuvant, in large part, by selectively binding to
the C5a receptor (C5aR/CD88) on APCs, resulting in their activation and subsequent
increase in processing and presentation of conjugated antigen. Thus, we
hypothesized that surface modification of biodegradable PLGA nanoparticles with
EP67 would increase the efficacy of immune responses against the encapsulated
antigen. To test this hypothesis, we encapsulated a model antigen ovalbumin (OVA)
in biodegradable PLGA nanoparticles, modified the surface of nanoparticles with
EP67 using the interfacial activity assisted surface functionalization (IAASF)
technique. We then compared the extent to which respiratory immunization with OVA
encapsulated in the EP67 surface-modified, unmodified nanoparticles or vehicle alone
protects naïve female C57Bl/6 mice against primary respiratory infection with
recombinant Listeria monocytogenes expressing soluble OVA (LM-OVA) and affects
the generation of systemic and mucosal cellular responses. Additionally, we have also
tested the effect that EP67 surface modification of nanoparticles has on their
internalization and activation of murine bone marrow-derived dendritic cells (BMDCs)
in vitro.

4.1 Surface modification of PLGA nanoparticles with EP67 improves
internalization by BMDCs.

Presentation of exogenous antigen to T cells requires the uptake of antigen by
antigen-presenting cells followed by processing and presentation in the context of
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MHC molecules [145, 146]. T-cell activation and memory development have also been
linked to the dose of antigen-experienced by dendritic cells [147, 148]. Therefore,
internalization of antigen by dendritic cells is an important parameter that affects the
efficacy of vaccines.

To determine if the surface modification of PLGA nanoparticles with EP67
affects the internalization of the NPs by murine BMDCs, we first encapsulated FITClabeled OVA (FITC-OVA) in PLGA NPs and modified the surface with reactive
maleimide groups by incorporating the diblock copolymer PLLA-PEG-MAL into the
NPs using IAASF technique (Table 4.1) (Fig 4.1A)[134]. Surface modification with
PLLA-PEG-MAL was confirmed by the presence of an ethylene glycol peak (3.8 ppm)
in the 1H-NMR NMR (Fig. 4.2). We then attached EP67 to the NPs using a Cys-GlyArg-Arg linker (PLGA NP-MAL-CGRR-EP67) (Fig 4.1B), and EP67 attachment to NPs
was then confirmed by amino acid analysis (Fig. 4.3). We next incubated murine
BMDCs (Day 8) with unmodified [NP(FITC-OVA)], scrambled EP67 (CGRRM[MeL]RYKPaFDS)-modified [scEP67-NP(FITC-OVA)], and EP67- modified [EP67NP(FITC-OVA)] nanoparticles for 2 h and compared the internalization by measuring
the proportion of BMDCs positive for FITC-OVA using flow cytometry. Internalization
of nanoparticles was significantly higher for EP67-modified (52%) when compared to
unmodified (40%; p≤0.05) or scEP67-modified (38%; p≤0.01) NPs (Fig. 4.5E). The
MFI of FITC in BMDCs treated at 37 oC was significantly higher for EP67-modified
(4953 AU) when compared to unmodified (2472; p≤0.01) or scEP67-modified (1918
AU; p≤0.01) NPs. To rule out false positives due to surface adsorption of NPs, we also
compared NP internalization and MFI of FITC in BMDCs treated with NPs at 4 oC (Figs
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4.5B, C). In contrast to treatment at 37 oC, there was no difference between the groups
when BMDCs were treated at 4 oC. Thus, surface modification with EP67 increases
the internalization of nanoparticles by BMDCs.

4.2 Surface modification of nanoparticles with EP67 activates BMDCs and
improves antigen presentation to T-cells.

Although the level of antigen uptake is an important criterion, it is not enough
to induce T-cell activation. For generating effective immune responses, it is necessary
that the antigen is presented to T-cells by activated antigen-presenting cells that have
upregulated expression of co-stimulatory molecules [145, 149]. Antigen presentation
in the absence of co-stimulation leads to T-cell anergy and induces antigen tolerance
[24, 150], an undesirable outcome for vaccination.

To determine if the surface modification of nanoparticles activates BMDCs, we
treated immature murine BMDCs with NP(OVA), scEP67-NP(OVA) and EP67NP(OVA) for 24 h and compared the surface expression levels of BMDC activation
markers CD80, CD86 and MHC II by flow cytometry (Fig. 4.6). The expression of
activation markers, as measured by MFI, was significantly higher on BMDCs treated
with EP67-NP(OVA) [CD80 – 43306 AU, CD86 – 1221 AU, MHC-II – 26491 AU] when
compared to BMDCs treated with NP(OVA) [CD80 – 19441 AU (p≤0.01), CD86 – 792
AU (p≤0.01), MHC II – 15295 AU (p≤0.01)], and scEP67-NP(OVA) [CD80 – 30607 AU
(p≤0.001), CD86 – 812 AU (p≤0.01), MHC-II – 20806 AU (p≤0.001)]. Thus, surface
modification of nanoparticles with EP67 activates BMDCs better than unmodified and
scEP67-modified nanoparticles.
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To determine if the activation of BMDCs by surface-modified nanoparticles
translates into increased antigen cross-presentation/presentation via the MHC I/II
pathways, we co-incubated nanoparticle-treated BMDCs with OVA-responsive T-cell
hybridomas CD8OVA1.3 (MHC-I/OVA257–264) and DOBW (MHC-II/OVA323-339) for 18 h
and compared the concentrations of IL-2 in the culture supernatant by ELISA. IL-2 is
secreted by T-cells upon T-cell receptor ligation by cognate peptide-MHC complexes
[151] on activated APCs, and therefore can be used as a surrogate for antigen
presentation [152]. The concentration of IL-2 was significantly higher in the
supernatants of DOBW cells (Fig. 4.7A) when co-incubated with EP67-NP(OVA)treated BMDCs [EP67-NP(OVA) -770.47 pg/mL; NP(OVA) -510.46 pg/mL (p≤0.001);
scEP67-NP(OVA) -460.41 pg/mL (p≤0.001)]. Similarly, the IL-2 concentrations in
CD8OVA1.3 cell supernatant (Fig. 4.7B) co-incubated with EP67-NP(OVA)-treated
BMDCs [96.34 pg/mL] was significantly higher when compared to CD8OVA1.3 cells
co-incubated with NP(OVA)- [59.90 pg/mL (p≤0.001)] and scEP67-NP(OVA)- [51.22
pg/mL (p≤0.001)] treated BMDCs. Thus, BMDCs treated with nanoparticles surfacemodified

with

EP67

were

significantly

better

at

antigen

cross-

presentation/presentation when compared to unmodified or scEP67-modified
nanoparticles.

4.3 Immunization with EP67 surface-modified OVA-encapsulated PLGA NPs
increases protection against primary mucosal infection with LM-OVA.

In our earlier studies, we found that EP67, when conjugated to a CD8+ T-cell
epitope, can be used as a mucosal adjuvant to improve protection against respiratory

57

infection with murine cytomegalovirus (MCMV) [74] and also that encapsulation of
EP67-conjugated CTL epitope in biodegradable nano- and micro- particles improves
protection against MCMV when compared to free vaccine [153]. However, the effect
of conjugating EP67 onto the surface of biodegradable NPs on the immune responses
generated against encapsulated antigen is not known.

Recombinant Listeria monocytogenes expressing ovalbumin (LM-OVA) has
been routinely utilized as a model pathogen to study the efficacy of novel immunization
strategies using ovalbumin as a model antigen [154, 155]. Although the natural route
of infection for Listeria monocytogenes is the oral route, mice were demonstrated to
be susceptible to intranasal challenge with peak bacterial titers in lungs, liver and
spleen on day 3[156]. Thus, the respiratory challenge with LM-OVA can be used as a
model for testing efficacy of mucosal immune responses generated by immunization.

To determine if surface modification of PLGA NPs with EP67 affects the
efficacy of immune response against the encapsulated antigen, we administered 6week old female C57Bl/6 mice with vehicle alone (PBS), encapsulated OVA NPs
(NP(OVA)) and encapsulated OVA NPs surface-modified with EP67 (EP67-NP(OVA))
in a volume (50 µL) which is expected to reach the total respiratory tract, including the
lungs [141] (Fig. 5A). We then infected the mice 14 days’ post-immunization with sublethal dose[156] (2 × 107 CFU/ 50µL) of Listeria monocytogenes expressing OVA (LMOVA) and compared peak bacterial titers in lungs, liver and spleen three days postinfection[156] (Fig. 4.8A).
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LM-OVA titers in mice immunized with EP67-NP(OVA) [2.751×108 CFU/g] in
lungs (Fig. 4.8B) were significantly lower when compared to NP(OVA)- [1.275×109
CFU/g; P = 0.0122] and PBS- [1.528×109 CFU/g; P = 0.0026] treated mice. In liver
(Fig. 4.8C) the titers in EP67-NP(OVA)- [2.724×106 CFU/g] treated mice were
significantly lower than in NP(OVA)- [1.430×108 CFU/g; P = 0.0099] treated mice and
no statistical difference when compared to PBS- [1.015×108 CFU/g; P = 0.0573]
treated mice. Similarly, in spleen (Fig. 4.8D), titers in EP67-NP(OVA) [2.529×107
CFU/g] treated mice were significantly lower than in NP(OVA) [1.738×10 8 CFU/g; P =
0.0028] treated mice; whereas there was no statistical difference when compared to
PBS- [9.242×107 CFU/g; P = 0.1356] treated mice. Thus, immunization with EP67
surface-modified nanoparticles increased the efficacy of immune response against the
encapsulated antigen.

4.4 Respiratory immunization with EP67 surface-modified OVA encapsulated
PLGA NPs increases the magnitude of mucosal and systemic antigen-specific
T-cells.

Effective protection against viral and intracellular bacterial infection requires
potent pathogen-specific CTL responses[14, 157]. Resistance to intravenous
challenge with LM-OVA, an intracellular pathogen, has been demonstrated to be
primarily due to OVA-specific CD8+ T-cells but not antigen-specific humoral
responses. Given that respiratory immunization with EP67-NP(OVA) increased
protection against respiratory challenge with LM-OVA, it is expected that respiratory
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immunization with EP67-NP(OVA) would increase the proportions of OVA-specific
systemic and mucosal T-cells.

To determine if respiratory immunization with EP67-NP(OVA) increases the
magnitude of OVA-specific T cell responses, we again administered mice with vehicle
alone (PBS), encapsulated OVA NPs (NP(OVA)) and encapsulated OVA NPs surfacemodified with EP67 (EP67-NP(OVA)) under the same dosage regimen (Fig. 5A). We
then compared the proportions of OVA-specific activated T cells, on the day of
infection (14 days post immunization), in lungs and spleen by staining with OVAspecific tetramers for CD4 (I-Ab / HAAHAEINEA) and CD8 (H-2Kb / SIINFEKL) and
analyzing by flow cytometry. Immunization with EP67-NP(OVA) generated a higher
proportion of CD4+CD44hitet+ cells in lungs (Fig. 4.9A) and spleen (Fig. 4.9B) by
about 0.5% and 2% over NP(OVA)- or PBS-treated animals. Furthermore, EP67NP(OVA) generated a higher proportion of CD8+CD44hitet+ cells than NP(OVA) or
PBS in lungs (Fig. 4.9C) by 0.2% and in spleen (Fig. 4.9D) by 0.8%. Thus, respiratory
immunization with EP67-NP(OVA) increases the proportion of systemic and mucosal
antigen-specific T-cells.

4.5 Respiratory immunization with EP67 surface-modified OVA-encapsulated
NPs affects CD127/KLRG1 memory subsets of systemic antigen-specific CD8+
and CD4+ T-cells.

Effective immunization against a pathogen requires the generation of a stable
pool of long-lived antigen-specific memory T-cells which can respond quickly to
protect against infection [158]. It is possible to identify memory precursor cells with the
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potential to become long-lived memory cells during the peak of T-cell response
generated post-immunization by analyzing the cell surface expression of IL-7Rα
(CD127) and KLRG1 [159, 160]. Based on CD127 and KLRG1 expression, T-cells
can be classified into early effector cells (EEC - CD127-KLRG1-), memory precursor
effector cells (MPEC - CD127+KLRG1-), short-lived effector cells (SLEC - CD127KLRG1+) and, double positive effector cells (DPEC - CD127+KLRG1+)[160, 161].
Although studies have shown that all the subsets have similar potential to clear
pathogens, only EECs and MPECs have the potential to become long-lived memory
cells[161].

To determine if respiratory immunization with EP67-NP(OVA) affects
CD127/KLRG1 memory subsets of systemic antigen-specific CD4+ and CD8+ T-cells,
we compared the proportions of CD127/KLRG1 subsets within the CD4+CD44+tet+
and CD8+CD44+tet+ cells generated in the spleens using flow cytometry. EP67NP(OVA) generated higher proportions of SLEC (CD4 - ~16% / CD8 - ~13%), DPEC
(CD4 - ~3% / CD8 - ~0.8%) and MPEC (CD4 - 5% / CD8 - ~38%) compared to
NP(OVA) (Fig. 4.10). On the other hand, the proportion of EEC was found to be higher
in NP(OVA) by ~23% in CD4+ cells and ~42% in CD8+ cells. Thus, surface
modification of PLGA NPs with EP67 affects the CD127/KLRG1 memory subsets of
systemic CD4+ and CD8+ T-cells.
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4.6 Respiratory immunization with EP67 surface-modified OVA-encapsulated
NPs affects CD127/KLRG1/CD62L memory subsets of systemic antigen-specific
CD8+ and CD4+ T-cells.

Activated antigen-specific CD44+ T-cells can also be classified into functionally
heterogeneous memory subsets based on the cell surface expression of CD127,
KLRG1, and lymph node homing receptor CD62L [162]. SLECs (SLEC– CD127KLRG1-CD62L-) have high cytolytic potential in vitro, but lack long-term survival.
Effector memory precursor cells (T EM MPEC- CD127+KLRG1-CD62L-) demonstrate
both cytolytic activity and long-term survival, whereas central memory precursor cells
(TCM MPEC- CD127+KLRG1-CD62L+) have low cytolytic activity but have long-term
survival and high homeostatic proliferation.

To determine if respiratory immunization with EP67-NP(OVA) affects
CD127/KLRG1/CD62L memory subsets of systemic antigen-specific CD4+ and CD8+
T-cells, we compared the proportions of CD127/KLRG1/CD62L subsets within the
CD4+CD44+tet+ and CD8+CD44+tet+ cells generated in the spleens using flow
cytometry. EP67-NP(OVA) generated higher proportions of T EM MPEC (CD4 - ~9% /
CD8 - ~28%), and TCM MPEC (CD4 – 0.3% / CD8 - ~2%) compared to NP(OVA) (Fig.
4.11). In contrast, the proportion of SLEC was found to be higher in NP(OVA) by ~8%
in CD4+ cells and ~2% in CD8+ cells. Thus, surface modification of PLGA NPs with
EP67 affects the CD127/CD62L memory subsets of systemic CD4+ and CD8+ T-cells.
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4.7 Respiratory immunization with EP67 surface-modified OVA encapsulated
NPs affects cytokine secretion profile of epitope responsive systemic T-cells.

To determine the effect of respiratory immunization with EP67-NP(OVA) on the
cytokine secretion profile of epitope responsive T-cells, we ex vivo restimulated the
splenocytes harvested 14 days post-immunization with the immunodominant OVA
CD4 epitope (ISQAVHAAHAEINEAGR) for 48 h and analyzed the supernatants for
Th1 (IL-2, IL-6) (Fig. 4.12A), Th17 (IL-17A, IL-22) (Fig. 4.12B) and Th2 (IL4, IL-5) (Fig.
4.12C) cytokines. Splenocytes isolated from EP67-NP(OVA) treated mice produced
significantly higher quantities of Th1 (~100%) and Th17 (~300%) cytokines when
compared to both PBS- and NP(OVA)-treated mice, whereas no difference was found
in the production of Th2 type cytokines. Thus, respiratory immunization with EP67NP(OVA) affects the cytokine secretion profile of CD4 epitope responsive T-cells and
shifts it towards Th1 and Th17 type responses.
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Figure 4.12 Synthetic strategy for modifying the surface of PLGA 50:50
nanoparticles with EP67
Endotoxin-free ovalbumin (OVA) was encapsulated in PLGA 50:50 nanoparticles by
the W/O/W emulsification / solvent extraction method. (A) Maleimide-activated 2 kDa
PEG linkers were added to the nanosphere surfaces during OVA encapsulation as
part of PLLA(10 kDa)-b-PEG(2 kDa)-maleimide diblock copolymers that were
physically partitioned into nascent PLGA 50:50 nanospheres before complete solvent
extraction and subsequent lyophilization. The extent that the surfaces of lyophilized
particles were functionalized with maleimide was determined by 1H-NMR (Fig.4.2).
(B) EP67 was activated with sulfhydryl groups by the addition of N-terminal Cys
through a Gly-Arg-Arg-linker and reacted with lyophilized maleimide-activated
nanospheres resuspended in PBS [pH 7.4]. The extent that the surfaces of lyophilized
particles were modified with EP67 was determined by amino-acid analysis (Fig.4.3).
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Figure 4.2 Surface functionalization of PLGA NPs with PLLA-PEG-MAL was
confirmed by the presence of PEG peak in the 1H-NMR spectra of the NPs
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Figure 4.3 Coating of maleimide functionalized NPs with EP67 was confirmed
by amino acid analysis of blank PLGA-EP67 NPs.
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Figure 4.4 Internalization of FITC-OVA loaded NPs by BMDCs.
NP(FITC-OVA), scEP67-NP(FITC-OVA) and EP67-NP(FITC-OVA) were incubated
with BMDCs on a cover slip placed inside a 24 well plate for 1h, washed 3X with
PBS, nuclei stained with DAPI and analyzed by confocal microscopy.
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Figure 4.13. Modifying the surface of PLGA 50:50 nanoparticles with EP67
increases internalization by immature murine bone marrow-derived DCs.
Immature BMDCs (male C57BL/6) were incubated at (A, B, C) 4°C or (D, E, F) 37°C
for 2 h with ~1.5 µg of endotoxin-free fluorescein-modified OVA (FITC-OVA) loaded
in ~20 μg of unmodified PLGA 50:50 nanoparticles [NP(FITC-OVA), dark grey bars],
PLGA 50:50 nanoparticles surface-modified with inactive scEP67 [scEP67-NP(FITCOVA), grey bars], or PLGA 50:50 nanoparticles surface-modified with EP67 [white
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bars, EP67-NP(FITC-OVA)] as described in Fig 4.1. Cells were rinsed with PBS,
stained with viability dye and PE-Cy5 anti-CD11c antibodies, then analyzed by flow
cytometry. Representative FACS data of median fluorescein staining EVENTS from
viable CD11c+ BMDCs incubated with the indicated nanoparticles for 2 h at (A) 4°C
or (D) 37°C. The average percent of total viable CD11c + BMDCs at (B) 4°C or (E)
37°C that were FITC-OVA+ ±SD (n=2 wells) and the average median fluorescence
intensities (MFI) of fluorescein staining of live CD11c +FITC-OVA+ BMDCs at (C) 4°C
or (F) 37°C ±SD (n=2) between treatment groups were compared by one-way
ANOVA with Dunnett’s post-test where *p ≤0.05 and **p ≤0.01. Data are
representative of at least three independent experiments.
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Figure 4.6 Modifying the surface of PLGA 50:50 nanoparticles with EP67
increases the expression of activation markers on the surface of immature
murine BMDCs
Immature BMDCs (male C57BL/6) were incubated at 37°C for 24 h with media alone
[black bars, Media] or media containing ~7.9 µg endotoxin-free OVA loaded in ~100
μg of uncoated PLGA 50:50 nanoparticles [dark grey bars, NP(OVA)], PLGA 50:50
nanoparticles surface-modified with inactive scEP67 [grey bars, scEP67-NP(OVA)],
or PLGA 50:50 nanoparticle surface-modified with EP67 [white bars, EP67-NP(OVA)].
BMDCs were then stained with viability dye, anti-CD11c, anti-CD80, anti-MHC-II and
anti-CD86 antibodies and analyzed by flow cytometry. Average median fluorescence
intensity ±SD (n=2) of staining CD11c+ cells with (A) PE-Cy5 anti-CD80, (B) antiCD86, or (C) anti-MHC II between the indicated treatment groups were compared
using one-way ANOVA with Dunnett’s post-test where **p≤0.01, ***p≤0.001, and
****p≤0.0001. Data are representative of at least three independent experiments.
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Figure 4.14. Modifying the surface of PLGA 50:50 nanoparticles with EP67
increases murine BMDC activation of model naïve T cells against encapsulated
protein in vitro.
Immature BMDCs (C57BL/6) were incubated at 37°C for 2 h with media alone [black
bars, Media] or media containing ~7.9 µg endotoxin-free OVA-loaded in ~ x mg
unmodified nanoparticles (~400 nm diam.) [NP(OVA), dark grey bars], nanoparticles
surface-modified with inactive scEP67 [scEP67-NP(OVA), grey bars] or nanoparticles
surface-modified with active EP67 [EP67-NP(OVA), white bars] through 2 kDa PEG
linkers (~0.3 wt% EP67). BMDCs were then washed and incubated with OVA-specific
CD4+ (DOBW) or CD8+ (CD8 OVA 1.3) T cell hybridomas for 18 h at 37°C. Average
concentrations of IL-2 ± SD (n=3) released into the media by (A) CD4 + (DOBW) or (B)
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CD8+ (CD8 OVA 1.3) T cells were determined by ELISA and compared between
treatment groups using one-way ANOVA with Dunnett’s post-test where **p≤0.01,
***p≤0.001, ****p≤0.0001.
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Figure 4.8 Modifying the surface of PLGA 50:50 nanoparticles with EP67
increases the efficacy of respiratory immunization
Modifying the surface of PLGA 50:50 nanoparticles with EP67 increases the efficacy
of respiratory immunization with encapsulated protein against primary respiratory
infection with L. monocytogenes that ectopically expresses OVA. (A) Vehicle alone
(PBS), or vehicle containing ~25 µg LPS-free OVA encapsulated in unmodified PLGA
50:50 nanoparticles [NP(OVA)] or PLGA 50:50 nanoparticles surface-modified with
EP67 [EP67-NP(OVA)] was administered to naïve female C57BL/6 mice (~6 wk old)
on Day 0 and Day 7 by IN administration (50 μL). Fourteen days after the final
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immunization (Day 21), L. monocytogenes ectopically expressing OVA (LM-OVA) was
administered IN (2 x 107 CFU in 50 µL) and peak titers of LM-OVA (Day 3 postinfection; Day 24) were determined by CFU assay. Average peak LM-OVA colony
forming units (CFU) per gram of tissue ± SD (n = 7 mice) in the (B) lungs, (C) liver,
and (D) spleen were compared using one-way ANOVA with uncorrected Fisher’s LSD
test. Data are representative of two independent experiments.
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Figure 4.15 Modifying the surface of PLGA nanoparticles with EP67 increases
proportions of antigen-specific mucosal and systemic T cells after respiratory
immunization.
Modifying the surface of PLGA 50:50 nanoparticles with EP67 increases proportions

of encapsulated protein-specific mucosal and systemic T cells after respiratory
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immunization. Naïve female C57BL/6 mice (~6 wk old) were immunized as described
in Fig.4.8. (Days 0 and 7) and sacrificed on the day of challenge (Day 21). Proportions
of (A, B) OVA-specific (tet+) CD4+CD44HI or (C, D) OVA-specific (tet+) CD8a+CD44hi
cells in the lungs and spleen were determined by flow cytometry. Average
percentages of CD4+CD44HItet+ cells and CD8+CD44HItet+ cells ±SD (n=4 mice)
between treatment groups were compared in the respective organs using one-way
ANOVA with uncorrected Fisher’s LSD test.
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Figure 4.10 Modifying the surface of PLGA nanoparticles with EP67 affects
CD127/KLRG1 memory subsets of mucosal T-cells.
Modifying the surface of PLGA nanoparticles with EP67 affects CD127/KLRG1
memory subsets of mucosal CD4+ and CD8+ T-cells generated against encapsulated
protein by respiratory immunization. Naïve female C57BL/6 mice (~6 wk old) were
immunized as in Fig. 5 and sacrificed on the day of challenge (Day 21). Average
percent of (A) CD4+CD44HITet+ or (B) CD8a+CD44HITet+ cells in the lungs that
were SLEC (CD127-KLRG1+), DPEC (CD127+KLRG1+), MPEC (CD127+KLRG1-),
or EEC (CD127-KLRG1-) ± SD (n=4 mice) were determined by flow cytometry and
compared using two-tailed unpaired t-test.
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Figure 4. 16 Modifying the surface of PLGA nanoparticles with EP67 affects
CD127/KLRG1/CD62L memory subsets of T cells.
Modifying

the

surface

of

PLGA

nanoparticles

with

EP67

affects

CD127/KLRG1/CD62L memory subsets of systemic CD4+ and CD8+ T cells generated
against encapsulated protein after respiratory immunization. Naïve female C57BL/6
mice (~6 wk old) were immunized as in Fig. 4.8 and sacrificed on the day of challenge
(Day 21). Average proportions of (A) CD4+CD44HITet+ or (B) CD8a+CD44HITet+ cells
in the spleen that were SLEC (CD127-KLRG1-CD62L-), TEM MPEC (CD127+KLRG1CD62L-), or TCM MPEC (CD127+KLRG1-CD62L+) ± SD (n=4 mice) were determined
by flow cytometry and compared using two-tailed unpaired t-test.
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Figure 4.17 Modifying the surface of PLGA nanoparticles with EP67 selectively
affects the cytokine secretion pattern of CD4+ epitope-responsive splenocytes.
Naïve female C57BL/6 mice (~6 wk old) were immunized as in Fig. 4.8. Splenocytes
were harvested on the day of infection (Day 21) and incubated with OVA CD4+ epitope
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for 48h. Average concentrations ±SD (n=4) of (A) Th1, (B) Th17, or (C) Th2 cytokines
in the media were determined by multiplex assay and compared using one-way
ANOVA with uncorrected Fisher’s LSD test. Results are representative of at least two
independent experiments.
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Table 4.1 Characteristics of OVA-encapsulated PLGA nanoparticles
Formulation

Loading
(µg/mg ± SD)

Diameter
(nm ± SD)

Polydispersity Index
(PDI ± SD)

Zeta Potential
(mV ± SD)

NP(OVA)

78 ± 3

332 ± 4

0.20 ± 0.02

-16.8 ± 0.5

scEP67-NP(OVA)

79 ± 2

432.8 ± 0.8

0.41 ± 0.03

-12.5 ± 0.6

EP67-NP (OVA)

78 ± 4

382 ± 7

0.171 ± 0.002

-13.3 ± 0.7

Peptide
Content
(µg/mg)
1.75 ± 0.2
0.99 ± 0.2
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CHAPTER 5

DISCUSSION
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This study provides evidence that surface modification of OVA encapsulated
nanoparticles with EP67 increases the efficacy of immune responses against OVA in
female C57BL/6 mice after respiratory immunization. We found that respiratory
immunization with EP67 surface modified OVA encapsulated PLGA nanoparticles (i)
increased protection against respiratory infection with OVA-expressing Listeria
monocytogenes by significantly reducing bacterial burden at mucosal (lungs) and
systemic (liver and spleen) sites (Fig 4.8), (ii) increased magnitudes of OVA-specific
CD4+/CD8+ T-cells in lungs and spleen (Fig 4.9), (iii) increased proportions of shortlived effector cells (SLECs), double positive effector cells (DPECs), memory precursor
effector cells (MPECs) and decreased early effector cells (EECs) in lungs (Fig 4.10),
(iv) increased effector memory MPECs and central memory MPECs without affecting
SLECs in spleen (Fig 4.11) and (v) affected the cytokine secretion profile of
splenocytes responsive to MHC II epitope of OVA (Fig 4.12).

Our study also provides evidence that surface modification of OVAencapsulated NPs with EP67 (i) increases internalization of nanoparticles by immature
BMDCs when compared to uncoated or inactive scEP67 coated nanoparticles (Fig.
4.5), (ii) increases activation of BMDCs, as measured by upregulation of activation
markers MHC-II, CD80 and CD86, when compared to uncoated or inactive scEP67
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coated nanoparticles (Fig. 4.6) and, (iii) increases antigen-presenting potential of
BMDCs, determined by activation of OVA-specific T-cell hybridomas CD8OVA1.3
(CD8+) and DOBW (CD4+) by BMDCs treated with to uncoated, inactive scEP67 or
EP67 coated nanoparticles (Fig. 4.7).

Dendritic cells are the most potent antigen-presenting cells that play a major
role in generating adaptive immune responses against invading pathogens. Several
studies have demonstrated that directing antigen to DCs by targeting pattern
recognition receptors (PRRs), using antibodies or PRR ligands, can enhance antigen
presentation and thus improve the efficacy of immunization. In our earlier studies, we
have shown that EP54-, a sister analog of EP67, containing vaccine constructs are
rapidly internalized via the C5aR present on human monocyte-derived DCs and
presented in the context of HLA I/II. Given that EP67 has a 1000-fold higher affinity to
C5aR than EP54, it is reasonable to expect that DCs will similarly internalize and
present EP67-containing vaccines. EP67 is also expected to improve antigen
processing and presentation directly by activating DCs and, indirectly by inducing DCs
to produce various cytokines and chemokines that favor a pro-inflammatory immune
response, as evidenced by the upregulation of maturation markers CD80, CD40, and
CD54, inducing secretion of chemokines (CCL2, CCL3, CCL4, CXCL8, and CXCL10)
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and cytokines (IL-6, IL-1β, TNF-α, and IL-10) by human monocyte-derived DCs
(unpublished data). These studies together can be used to explain the results of our
current study. EP67 on the surface of NPs upon interaction with C5aR on antigen
presenting cells (i) induces receptor-mediated internalization of NPs, (ii) followed by
activation of APCs resulting in increased surface expression of antigen-presenting
molecules and, consequently, (iii) better activation of CD4+ and CD8+ T-cells resulting
in enhanced immune responses against the encapsulated antigen.

The effective immune response against an invading pathogen involves the
generation of a large pool of pathogen-specific effector T-cells (TEFF), some of which,
after the infection is resolved, transition into effector memory (T EM) and central
memory cells (TCM) with high proliferative and survival potential. Although, the rate of
transition from TEFF to TEM and TCM depends on the nature of immunization and
presence of antigen, the long-term fate of TEFF cells is decided during the initial phase
of T-cell activation. The long-term fate of T-cells depends on the duration of initial DCT-cell interactions which is affected by the dose of antigen-experienced by DCs. Tcells that interact with DCs exposed to high antigen dose are expected to differentiate
into memory T-cells.
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Keeping the above information in mind, the increased memory precursor
effector cells observed after respiratory immunization with EP67 surface-modified NPs
when compared to unmodified NPs may be due to faster translocation of EP67 surface
modified NPs across the respiratory epithelium, through M-cells which may express
C5aR alike intestinal M-cells, into mucosal-associated lymphoid tissue (MALT) which
is rich in the lymphoid cells required to generate an immune response. The higher
proportions of MPECs can also be explained by increased uptake of EP67 surfacemodified NPs by mucosal APCs through C5aR, and this is supported in part, by the
increased internalization of EP67 surface-modified NPs by BMDCs in vitro observed
in this study. However, the effect of particle size on internalization by APCs and
trafficking across epithelium cannot be overlooked. As such, both unmodified and
EP67 surface modified NPs are in the optimal size range required for APC
phagocytosis and translocation across the epithelium (although not receptor mediated
in the case of unmodified NP), therefore it is possible that EP67 surface modification
is only accelerating the transition of effector cells into memory precursors, as
supported by the higher proportion of early effector cells in the unmodified NP-treated
animals (Fig. 4.9).
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CHAPTER 6

CONCLUSIONS AND FUTURE DIRECTIONS
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6.1 Summary and Conclusions
Vaccination is one of the most effective ways to prevent infectious diseases,
however, there are several diseases against which conventional vaccination
strategies have failed to generate effective immune responses or have a low safety
profile. Furthermore, conventional vaccines consisting of live attenuated or
inactivated pathogens are difficult to develop and have the potential to revert to
pathogenicity. Subunit vaccines composed of antigenic proteins or peptides can
potentially overcome the limitations of conventional vaccines, but have limited
efficacy because of low immunogenicity, inability to generate T-cell immunity, rapid
clearance from administration site and insufficient delivery to antigen presenting
cells. Thus, there is an urgent need to develop novel strategies that can overcome
the disadvantages of subunit vaccines.
In this study, we report the development of C5aR-targeted biodegradable
PLGA nanoparticles that improve the efficacy of respiratory immunization by
enhancing the immune responses generated against the encapsulated model
antigen ovalbumin. We have shown that surface modification of PLGA nanoparticles
with C5aR ligand EP67 will increase the internalization of nanoparticles by BMDCs
and simultaneously activate BMDCs as shown by the upregulation of MHC II and
costimulatory molecules. The activated BMDCs also appear to have higher antigenpresenting potential as shown by the increased secretion of IL-2 by OVA-specific Tcell hybridomas DOBW and CD8 OVA1.3.

Furthermore, we have demonstrated respiratory immunization with EP67
surface-modified OVA-encapsulated PLGA nanoparticles (i) increased protection
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against respiratory infection with LM-OVA by significantly reducing bacterial numbers
(ii) increased magnitudes of OVA-specific CD4+/CD8+ T-cells in lungs and spleen, (iii)
increased proportions of short-lived effector cells (SLECs), double positive effector
cells (DPECs), memory precursor effector cells (MPECs) in lungs, (iv) increased
effector memory MPECs and central memory MPECs without affecting SLECs in
spleen and (v) affected the cytokine secretion profile of splenocytes responsive to
MHC-II epitope of OVA.

In summary, our findings suggest that surface modification of biodegradable
nanoparticles increases the efficacy of respiratory immunization against the
encapsulated antigen by increasing magnitude and proportions of memory precursor
effector cells, which have the highest potential to become long-lived memory cells,
and provide long-term immunity. Thus, surface modification of biodegradable
nanoparticles encapsulating the desired antigen with EP67 may be an effective
approach to increase the efficacy of mucosal vaccines,
6.2 Future Directions
Although the work presented here demonstrates the proof of concept that
surface modification of PLGA nanoparticles can increase the efficacy of respiratory
immunization against the encapsulated antigen, the formulation by itself is not
optimized. It is important to understand the effect of different formulation parameters
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like the size of the particle, release rate of antigen, the length of PEG cross-linker
and the extend of surface modification with EP67 will have on the immune
responses. Therefore, the next step would be to modify the above-mentioned
parameters and optimize the vaccine formulation. After an optimized formulation is
achieved, the next goal is to test the efficacy of the formulation in protecting mice
from respiratory infection with murine cytomegalovirus, using protective antigens
from MCMV as the encapsulated antigen, when compared to immunization with coadministration of inactivated virus with EP67.
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